4-AcO-MiPT
4-acetoxy-N-methyl-N-isopropyltryptamine
Studies and references cited across this article, graded by evidence strength.
Inconclusive means the cited source neither confirms nor refutes the claim — a lower-confidence badge, not an error.
Data points an editor reviewed and accepted for publication.
Value Provenance
Dosing
oraltrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Threshold | 5 mg | 5 mg | low |
| Low | 10–15 mg | 10–15 mg | low |
| Common | 15–20 mg | 15–20 mg | low |
| Strong | 20–35 mg | 20–35 mg | low |
| Heavy | 35+ mg | 35+ mg | low |
| Editorial | All dose values from community consensus via PsychonautWiki, confirmed consistent across multiple community sources. No controlled dose-finding study exists. These are existing database values being carried forward. Threshold 5 mg, light 10-15 mg, common 15-20 mg, strong 20-35 mg, heavy 35+ mg. | ||
ReasoningReasoningAll dose values from community consensus via PsychonautWiki, confirmed consistent across multiple community sources. No controlled dose-finding study exists. These are existing database values being carried forward. Threshold 5 mg, light 10-15 mg, common 15-20 mg, strong 20-35 mg, heavy 35+ mg. Evidence basis: community_consensus_large | |||
Duration
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 20–60 minutes | 20–60 minutes | low |
| Editorial | Community consensus via PsychonautWiki: onset 20-60 minutes oral. No controlled PK data. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: onset 20-60 minutes oral. No controlled PK data. Evidence basis: community_consensus_large | |||
| Offsettrace | 1–2 hours | 1–2 hours | low |
| Editorial | Community consensus via PsychonautWiki: offset 1-2 hours oral. No controlled data. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: offset 1-2 hours oral. No controlled data. Evidence basis: community_consensus_large | |||
| Totaltrace | 4–8 hours | 4–8 hours | low |
| Editorial | Community consensus via PsychonautWiki: total duration 4-8 hours oral. This represents subjective experience duration, not pharmacological half-life. Consistent with Shulgin's reported 4-6 hour duration for 4-HO-MiPT. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: total duration 4-8 hours oral. This represents subjective experience duration, not pharmacological half-life. Consistent with Shulgin's reported 4-6 hour duration for 4-HO-MiPT. Evidence basis: community_consensus_large | |||
| Come uptrace | 1–2 hours | 1–2 hours | low |
| Editorial | Community consensus via PsychonautWiki: come-up 1-2 hours oral. No controlled data. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: come-up 1-2 hours oral. No controlled data. Evidence basis: community_consensus_large | |||
| Peaktrace | 1.5–3 hours | 1.5–3 hours | low |
| Editorial | Community consensus via PsychonautWiki: peak 1.5-3 hours oral. No controlled data. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: peak 1.5-3 hours oral. No controlled data. Evidence basis: community_consensus_large | |||
| After effectstrace | 2–4 hours | 2–4 hours | low |
| Editorial | Community consensus via PsychonautWiki: after-effects 2-4 hours oral. Residual effects after subjective experience ends. | ||
ReasoningReasoningCommunity consensus via PsychonautWiki: after-effects 2-4 hours oral. Residual effects after subjective experience ends. Evidence basis: community_consensus_large | |||
Safety
Toxicity Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Acute | low | low | low |
| Chronic | low | low | low |
| Organs Affected | cardiovascular | cardiovascular | low |
| Editorial | No substance-specific toxicity data exist. Classification based on class-level tryptamine NPS toxicity review (Tittarelli 2015) and absence of adverse event reports in NPS surveillance (Mohr 2022, Helander 2014). Downgraded one level per evidence discount rule — all data is class extrapolation from the broader serotonergic tryptamine class, not 4-AcO-MiPT-specific. | ||
ReasoningReasoningNo substance-specific toxicity data exist. Classification based on class-level tryptamine NPS toxicity review (Tittarelli 2015) and absence of adverse event reports in NPS surveillance (Mohr 2022, Helander 2014). Downgraded one level per evidence discount rule — all data is class extrapolation from the broader serotonergic tryptamine class, not 4-AcO-MiPT-specific. Evidence basis: structural_analogy | |||
Dependence Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Physical | none | none | medium |
| Psychological | negligible | negligible | medium |
| Compulsive Redosing | negligible | negligible | medium |
| Dose Escalation | negligible | negligible | medium |
| Editorial | No substance-specific dependence data. Classification based on consistent class-level evidence: serotonergic psychedelics (psilocybin, LSD, DMT) show negligible dependence liability across multiple assessment frameworks. Gatch et al. (2021) noted abuse liability 'similar to DOM' based on drug discrimination, but this refers to stimulus generalization, not compulsive use. Rapid 5-HT2A tolerance is a pharmacological barrier to dose escalation (Wallach 2023). | ||
ReasoningReasoningNo substance-specific dependence data. Classification based on consistent class-level evidence: serotonergic psychedelics (psilocybin, LSD, DMT) show negligible dependence liability across multiple assessment frameworks. Gatch et al. (2021) noted abuse liability 'similar to DOM' based on drug discrimination, but this refers to stimulus generalization, not compulsive use. Rapid 5-HT2A tolerance is a pharmacological barrier to dose escalation (Wallach 2023). Evidence basis: structural_analogy | |||
Withdrawal Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Severity | none | none | medium |
| Symptoms | — | — | medium |
| Fatal | No | No | medium |
| Medical Supervision | Not required | Not required | medium |
| Editorial | No evidence of withdrawal syndrome for any serotonergic psychedelic tryptamine. Class-level confidence. | ||
ReasoningReasoningNo evidence of withdrawal syndrome for any serotonergic psychedelic tryptamine. Class-level confidence. Evidence basis: structural_analogy | |||
Tolerance Profiletrace
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Buildup | rapid | rapid | low |
| Half-life | 3 days | 3 days | low |
| Full Reset | 7 days | 7 days | low |
| Cross-tolerances | psilocybin, psilocin, LSD, DMT, 4-AcO-DMT, mescaline | psilocybin, psilocin, LSD, DMT, 4-AcO-DMT, mescaline | low |
| Editorial | Tolerance mechanism (5-HT2A downregulation) is well-established for the psychedelic class (Wallach 2023). Specific timing values (3-day half-life, 7-day reset) are community consensus consistent with the mechanism but not directly measured for 4-AcO-MiPT. Cross-tolerance with other serotonergic psychedelics expected via shared receptor target. | ||
ReasoningReasoningTolerance mechanism (5-HT2A downregulation) is well-established for the psychedelic class (Wallach 2023). Specific timing values (3-day half-life, 7-day reset) are community consensus consistent with the mechanism but not directly measured for 4-AcO-MiPT. Cross-tolerance with other serotonergic psychedelics expected via shared receptor target. Evidence basis: community_consensus_large | |||
Effects & Profile
Contraindications
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| psychiatric psychotic disorderstrace | absolute | absolute | medium |
| Editorial | Class-level contraindication for all serotonergic psychedelics. No substance-specific data but mechanism is consistent via 5-HT2A partial agonism. | ||
ReasoningReasoningClass-level contraindication for all serotonergic psychedelics. No substance-specific data but mechanism is consistent via 5-HT2A partial agonism. | |||
| psychiatric bipolar disordertrace | relative | relative | low |
| Editorial | Class-level contraindication for serotonergic psychedelics. No 4-AcO-MiPT-specific data. | ||
ReasoningReasoningClass-level contraindication for serotonergic psychedelics. No 4-AcO-MiPT-specific data. | |||
| other concurrent MAOI usetrace | absolute | absolute | medium |
| Editorial | Class-level absolute contraindication for serotonergic psychedelics. Supported by Tittarelli (2015) tryptamine toxicity review identifying MAOI combination as high-severity risk. | ||
ReasoningReasoningClass-level absolute contraindication for serotonergic psychedelics. Supported by Tittarelli (2015) tryptamine toxicity review identifying MAOI combination as high-severity risk. | |||
| other concurrent tramadol usetrace | absolute | absolute | medium |
| Editorial | Mechanistically well-supported dangerous interaction. Tramadol SERT inhibition (Baldo 2018) + 5-HT2A agonism = serotonin syndrome risk. Malcolm (2022) identifies this as clinically important DDI category. | ||
ReasoningReasoningMechanistically well-supported dangerous interaction. Tramadol SERT inhibition (Baldo 2018) + 5-HT2A agonism = serotonin syndrome risk. Malcolm (2022) identifies this as clinically important DDI category. | |||
| other concurrent SSRI/SNRI usetrace | relative | relative | medium |
| Editorial | Class-level interaction for all serotonergic psychedelics. Malcolm (2022) identifies psychedelic + serotonergic drug combinations as clinically important. | ||
ReasoningReasoningClass-level interaction for all serotonergic psychedelics. Malcolm (2022) identifies psychedelic + serotonergic drug combinations as clinically important. | |||
| cardiovascular cardiovascular diseasetrace | relative | relative | low |
| Editorial | Class-level cardiovascular concern for serotonergic tryptamines. Community reports confirm pupil dilation (sympathomimetic marker). No substance-specific cardiovascular data. | ||
ReasoningReasoningClass-level cardiovascular concern for serotonergic tryptamines. Community reports confirm pupil dilation (sympathomimetic marker). No substance-specific cardiovascular data. | |||
| pregnancy breastfeeding pregnancy and breastfeedingtrace | absolute | absolute | low |
| Editorial | No substance-specific or class-specific reproductive safety data. Precautionary contraindication applied universally for unstudied psychoactive compounds. | ||
ReasoningReasoningNo substance-specific or class-specific reproductive safety data. Precautionary contraindication applied universally for unstudied psychoactive compounds. | |||
Timeline Phases
oral
| Field | Published | AI Proposed | Confidence |
|---|---|---|---|
| Onsettrace | 1200–3600 sec(i=0.05) | 1200–3600 sec(i=0.05) | low |
| Editorial | All timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | ||
ReasoningReasoningAll timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | |||
| Come uptrace | 3600–7200 sec(i=0.35) | 3600–7200 sec(i=0.35) | low |
| Editorial | All timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | ||
ReasoningReasoningAll timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | |||
| Peaktrace | 5400–10800 sec(i=1.00) | 5400–10800 sec(i=1.00) | low |
| Editorial | All timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | ||
ReasoningReasoningAll timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | |||
| Resolutiontrace | 3600–7200 sec(i=0.20) | 3600–7200 sec(i=0.20) | low |
| Editorial | All timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | ||
ReasoningReasoningAll timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | |||
| Afterglowtrace | 7200–14400 sec(i=0.05) | 7200–14400 sec(i=0.05) | low |
| Editorial | All timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | ||
ReasoningReasoningAll timing data from community reports via PsychonautWiki: onset 20–60 min, come-up 1–2 h, peak 1.5–3 h, offset 1–2 h, after-effects 2–4 h, total 4–8 h. No controlled pharmacokinetic or dose-finding studies exist. Community values used directly as primary anchor per instructions. | |||
Dose Tier Summaries
At threshold doses (5 mg oral), effects are subtle and easily missed: a mild brightening of color perception, slight mood elevation, and a faint sense of altered awareness that may be difficult to distinguish from placebo. Mild pupil dilation may be detectable. Physically, effects are sub-perceptual to barely perceptual. No significant body load, visual distortion, or cognitive impairment is expected at this level.
Threshold value (5 mg oral) from community reports via PsychonautWiki. No controlled dose-finding data exist. Description inferred from class-typical tryptamine threshold effects and community report patterns.
ReasoningReasoning
Threshold value (5 mg oral) from community reports via PsychonautWiki. No controlled dose-finding data exist. Description inferred from class-typical tryptamine threshold effects and community report patterns.
Evidence basis: community_consensus_large
At light doses (10–15 mg oral), the first clearly psychedelic effects emerge: gentle color enhancement, subtle visual drifting of textures and surfaces, mild music enhancement, and a noticeable shift in thought patterns toward increased connectivity and novelty. Emotional responses begin to intensify. Physically, spontaneous body sensations — a tingling or rushing quality — may appear alongside mild yawning. Some users report nasal congestion and watery eyes. Mild sedation is common at the lower end of this range. Functional impairment is minimal but present.
Light dose range (10–15 mg oral) from community consensus via PsychonautWiki. Effects description synthesized from community effect taxonomy and Shulgin's account of 12 mg 4-HO-MiPT. No controlled data.
ReasoningReasoning
Light dose range (10–15 mg oral) from community consensus via PsychonautWiki. Effects description synthesized from community effect taxonomy and Shulgin's account of 12 mg 4-HO-MiPT. No controlled data.
Evidence basis: community_consensus_large
At common doses (15–20 mg oral), the full psychedelic experience manifests: pronounced color enhancement and brightness alteration, visual drifting and symmetrical texture repetition across surfaces, tracers behind moving objects, and emerging internal hallucinations with eyes closed. Auditory distortion and music enhancement become prominent. Thought connectivity intensifies, with pattern recognition enhancement and conceptual thinking producing novel associations. Emotional enhancement is marked — music, social interactions, and natural environments may feel deeply meaningful. Spontaneous body sensations are more pronounced, with the characteristic tingling/rushing quality. Pupil dilation is clearly visible. Yawning is common. The experience requires 4–8 hours of commitment; sleep is difficult until effects fully resolve.
Common dose range (15–20 mg oral) from community consensus via PsychonautWiki. Effects description drawn from community effect taxonomy. No controlled dose-response data.
ReasoningReasoning
Common dose range (15–20 mg oral) from community consensus via PsychonautWiki. Effects description drawn from community effect taxonomy. No controlled dose-response data.
Evidence basis: community_consensus_large
At strong doses (20–35 mg oral), visual effects dominate: intense symmetrical texture repetition, perspective distortion, depth perception distortion, and vivid internal hallucinations. Synesthesia — sensory crossover between modalities — may emerge. After-images and visual diffraction become prominent. Cognitive effects intensify toward immersion enhancement and potential thought loops. Transpersonal experiences — including unity and interconnectedness, existential realization, and occasionally entity contact — become possible at this range. Memory suppression can make the experience difficult to recall in detail. Physically, wakefulness replaces sedation at higher doses. The body load is more pronounced. Delusions may occur, and the experience can become overwhelming without supportive set and setting.
Strong dose range (20–35 mg oral) from community consensus via PsychonautWiki. Effects taxonomy includes transpersonal and high-intensity perceptual effects expected at this range. No controlled data.
ReasoningReasoning
Strong dose range (20–35 mg oral) from community consensus via PsychonautWiki. Effects taxonomy includes transpersonal and high-intensity perceptual effects expected at this range. No controlled data.
Evidence basis: community_consensus_large
At heavy doses (35+ mg oral), 4-AcO-MiPT produces an intense and potentially disorienting psychedelic experience. Visual field saturation with geometric patterning, profound perspective and depth perception distortion, vivid entity contact experiences, and complete immersion in internal hallucinations are reported. Thought loops and delusions become more likely. Emotional responses may swing unpredictably between euphoria, terror, and awe. Memory suppression is significant. Physical effects include pronounced pupil dilation, wakefulness, and autonomic arousal. The risk of acute psychological distress escalates substantially. This dose range should only be considered by individuals with extensive psychedelic experience in fully supported settings.
Heavy dose threshold (35+ mg oral) from community consensus via PsychonautWiki. Effects extrapolated from strong-dose community reports with expected intensification. No controlled data exist at any dose level. Higher risk profile inferred from class-level psychedelic safety data.
ReasoningReasoning
Heavy dose threshold (35+ mg oral) from community consensus via PsychonautWiki. Effects extrapolated from strong-dose community reports with expected intensification. No controlled data exist at any dose level. Higher risk profile inferred from class-level psychedelic safety data.
History
backfill Jun 4, 2026
Historical versions do not record which reviewer approved them; editorial accountability is recorded per value in the database and in the publication ledger going forward.
Sources
- [1]moderatePharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and SERTKozell LB, Eshleman AJ, Swanson TL, Bloom SH, Wolfrum KM, et al. · 2023 · Journal of Pharmacology and Experimental Therapeutics
- [2]weakSerotonin toxicity of serotonergic psychedelics: multi-jurisdiction legal and drug-drug interaction reviewPsychonautWiki editorial · 2025linkno claims checked
- [3]moderateIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potentialWallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, et al. · 2023 · Nature Communicationsdoi.org/10.1038/s41467-023-44016-1pubmed 3810210716 claims checked12 verified3 partial1 inconclusive
- [4]moderateSerotonin toxicity of serotonergic psychedelicsMalcolm B, Thomas K · 2022 · Psychopharmacology
- [5]weak
- [6]moderateThe fumarate salts of the N-isopropyl-N-methyl derivatives of DMT and psilocinChadeayne AR, Pham DNK, Golen JA, Manke DR · 2019 · Acta Crystallographica Section E Crystallographic Communications
- [7]moderateBis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocinChadeayne AR, Pham DNK, Golen JA, Manke DR · 2020 · Acta Crystallographica Section E: Crystallographic Communications
- [8]strongBehavioral effects of three synthetic tryptamine derivatives in rodentsHill RD, Shetty RA, Sumien N, Priddy J, Forster MJ, Gatch MB · 2025 · Journal of Psychopharmacology
- [9]moderateInvestigation of the Structure-Activity Relationships of Psilocybin AnaloguesKlein AK, Chatha M, Laskowski LJ, Anderson EI, Brandt SD, Chapman SJ, McCorvy JD, Halberstadt AL · 2021 · ACS Pharmacology & Translational Science
- [10]moderateDiscriminative Stimulus Effects of Substituted Tryptamines in RatsGatch MB, Hoch A, Carbonaro TM · 2021 · ACS Pharmacology & Translational Science
- [11]weakPubChem Compound Record: 4-AcO-MiPT (CID 46783587)National Center for Biotechnology Information · 2024linkno claims checked
- [12]strongPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter MechanismsInserra A, De Gregorio D, Gobbi G · 2021 · Pharmacological Reviews
- [13]moderateHuman Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by LC-HRMS/MSMalaca S, Huestis MA, Lattanzio L, Marsella LT, Tagliabracci A, Carlier J, Busardo FP · 2022 · Metabolites
- [14]strongPharmacokinetics of Psilocybin: A Systematic ReviewMeshkat S, Al-Shamali H, Perivolaris A, et al. · 2025 · Pharmaceutics
- [15]moderateReports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A ReviewMohr ALA, Logan BK, Fogarty MF, Krotulski AJ, Papsun DM, et al. · 2022 · Journal of Analytical Toxicology
- [16]moderateRecreational use, analysis and toxicity of tryptamines.Tittarelli R, Mannocchi G, Pantano F, Romolo FS · 2015 · Current neuropharmacology
- [17]moderateOpioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effectsBaldo BA · 2018 · Archives of Toxicology
- [18]strongTramadol and mental health: A systematic review of case reports describing psychological side-effectsGudla SS, Bhumireddy SKA, Vadaga AK · 2026 · International Journal of Psychiatry in Medicine
- [19]moderateDetection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA projectHelander A, Backberg M, Hulten P, Al-Saffar Y, Beck O · 2014 · Forensic Science International
- [20]weak
Claim Verification
Citation-bearing claims in this article were checked by an AI model against the abstract of the source they cite — every safety-critical claim, plus a sample of the rest. Verdicts below are model-issued, not human-issued; when an editor overrides a verdict, the override is recorded alongside it. Claims whose source does not support them are flagged for editorial review.
summary10 claims4verified1partial5inconclusive
inconclusiveThe first direct receptor pharmacology data were published only in 2023.[1]model confidence 70%
The abstract describes a receptor pharmacology study of 21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT, which is consistent with this being the pivotal 2023 paper. However, the publication year and 'first' status cannot be verified from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe parent ester binds 5-ht2a with moderate affinity (Ki = 800 ± 100 nM) and functions as a partial Gq agonist (69.2% efficacy), while the hydrolysis metabolite 4-OH-MiPT demonstrates approximately 7-fold higher affinity (Ki = 113 ± 31 nM) — consistent with prodrug activation[1]model confidence 75%
The abstract confirms this paper measures 5-HT2A binding for substituted tryptamines including 4-substituted compounds, which is the right paper for this claim. However, the specific Ki values and efficacy percentages are in the full-text tables, not the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGq-pathway signaling at 5-HT₂A, rather than beta-arrestin2 recruitment, predicts psychedelic potential in this compound class.[3]model confidence 98%
The abstract directly and explicitly states that 5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential, which is a verbatim match to the claim.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
partialNo LD₅₀ data exist for 4-AcO-MiPT in any species, and no adverse event case reports specific to this compound have been published. tolerance develops rapidly via 5-HT₂A downregulation, with community consensus suggesting full reset within approximately 7 days[3]model confidence 70%
The abstract mentions receptor downregulation and tachyphylaxis, but specifically attributes this to beta-arrestin-biased ligands, not to Gq agonists like 4-AcO-MiPT. The abstract does not address LD50 data, adverse event case reports, or the 7-day reset figure — these claims require separate sourcing.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCo-administration with serotonergic agents — particularly MAOIs and tramadol — carries mechanistically supported serotonin-syndrome risk[4]model confidence 85%
The abstract directly evaluates drug-drug interaction risks and serotonin toxicity with serotonergic psychedelics, including MAOI interactions. Tramadol is not specifically named but the abstract covers the mechanistic category the claim invokes.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs. Important for MDMA-SSRI and MDMA-MAOI interaction assessment.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe parent ester binds 5-ht2a with moderate affinity (Ki = 800 ± 100 nM) and functions as a partial Gq agonist (69.2% efficacy), while the hydrolysis metabolite 4-OH-MiPT demonstrates approximately 7-fold higher affinity (Ki = 113 ± 31 nM) — consistent with prodrug activation[1]model confidence 65%
Abstract confirms the paper measures 5-HT2A binding for 4-substituted tryptamines including parent and metabolite forms, but does not provide the specific Ki values (800 ± 100 nM, 113 ± 31 nM) or Gq efficacy percentage (69.2%) needed to verify this claim. These numbers would be in the full paper's data tables.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGq-pathway signaling at 5-HT₂A, rather than beta-arrestin2 recruitment, predicts psychedelic potential in this compound class.[3]model confidence 98%
Abstract directly and explicitly states that 5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response — a near-verbatim match to the claim.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveNo LD₅₀ data exist for 4-AcO-MiPT in any species, and no adverse event case reports specific to this compound have been published. tolerance develops rapidly via 5-HT₂A downregulation, with community consensus suggesting full reset within approximately 7 days[3]model confidence 60%
Abstract supports the 5-HT₂A receptor downregulation mechanism for tolerance/tachyphylaxis, but cannot verify the compound-specific LD₅₀ absence, the adverse event literature gap, or the '7 days' community consensus figure — these are separate empirical claims not addressed in the abstract.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCo-administration with serotonergic agents — particularly MAOIs and tramadol — carries mechanistically supported serotonin-syndrome risk[4]model confidence 85%
Abstract confirms the paper evaluates serotonin toxicity risks between psychedelic serotonergic substances and serotonergic drugs including MAOIs, directly supporting the mechanistic serotonin syndrome risk claim. Tramadol is not named in the abstract but the broader serotonergic interaction principle is covered.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs. Important for MDMA-SSRI and MDMA-MAOI interaction assessment.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe first direct receptor pharmacology data were published only in 2023.[1]model confidence 60%
Abstract confirms the paper is about receptor pharmacology of 21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT — the right topic — but provides no information to verify the temporal claim that this was the 'first' such data or that it was published in 2023.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
history14 claims11verified3inconclusive
verifiedChadeayne and colleagues published the crystal structure of 4-HO-MiPT fumarate monohydrate in 2019, followed by a second crystalline form — the bis(miprocinium) fumarate salt — in 2020[6]model confidence 85%
The abstract directly confirms this paper reports the crystal structure of 4-HO-MiPT fumarate monohydrate. The year (2019) and reference to a second subsequent form cannot be verified from the abstract, but the core crystal structure claim is clearly supported.
Solid-state crystal structures of MiPT fumarate and 4-HO-MiPT fumarate monohydrate. Both cations feature side-chain disorder. N-H...O and O-H...O hydrogen bonds generate infinite 2D networks.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedChadeayne and colleagues published the crystal structure of 4-HO-MiPT fumarate monohydrate in 2019, followed by a second crystalline form — the bis(miprocinium) fumarate salt — in 2020[7]model confidence 88%
The title explicitly names this 'a new crystalline form of miprocin' and the abstract confirms a crystal structure of 4-HO-MiPT fumarate salt, directly supporting the 'second crystalline form' component of the claim.
Crystal structure of 4-HO-MiPT fumarate salt. Tryptammonium and fumarate ions in 1D chains via hydrogen bonds.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn 2021, Klein et al. conducted a structure-activity relationship study of psilocybin analogs encompassing the 4-AcO/4-HO tryptamine class, and Gatch et al. examined discriminative stimulus properties of substituted tryptamines in rats, establishing that 4-hydroxy forms are consistently more potent than 4-acetoxy counterparts.[9]model confidence 90%
The abstract confirms this is an SAR study of 17 tryptamines with 4-hydroxy or 4-acetoxy groups, which is exactly the compound class described. The year (2021) cannot be verified from the abstract.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn 2021, Klein et al. conducted a structure-activity relationship study of psilocybin analogs encompassing the 4-AcO/4-HO tryptamine class, and Gatch et al. examined discriminative stimulus properties of substituted tryptamines in rats, establishing that 4-hydroxy forms are consistently more potent than 4-acetoxy counterparts.[10]model confidence 92%
The abstract directly confirms the Gatch et al. drug discrimination study in rats with the key finding that 4-hydroxy compounds are more potent than 4-acetoxy compounds.
4-hydroxy compounds more potent than 4-acetoxy. 4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThe pivotal dataset appeared in 2023, when Kozell et al. published the first binding affinity and functional potency data measured directly for 4-AcO-MiPT and 4-OH-MiPT at 5-ht2a, 5-ht2c, 5-ht1a, and serotonin-transporter[1]model confidence 85%
The abstract confirms this paper measured 21 substituted tryptamines at exactly the four targets listed (5-HT1A, 5-HT2A, 5-HT2C, SERT). The 2023 date and 'first' designation cannot be confirmed from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn the same year, Wallach et al. identified Gq-pathway signaling as the key predictor of psychedelic potential across the tryptamine class[3]model confidence 97%
The abstract directly states that 5-HT2A-Gq efficacy predicts psychedelic potential, confirming this key finding.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveMost recently, Hill et al. (2025) reported behavioral effects of 4-OH-MiPT in rodent drug discrimination and locomotor models following its designation by the DEA as a tryptamine derivative of concern.[8]model confidence 65%
The abstract confirms drug discrimination research of novel tryptamines using DOM as reference, consistent with this type of study. However, 4-OH-MiPT is not specifically named, locomotor activity assays are not mentioned, and the DEA designation context is absent from the abstract.
DOM used as reference hallucinogen for drug discrimination of novel tryptamines.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedChadeayne and colleagues published the crystal structure of 4-HO-MiPT fumarate monohydrate in 2019, followed by a second crystalline form — the bis(miprocinium) fumarate salt — in 2020[6]model confidence 88%
Abstract confirms this paper reports the crystal structure of 4-HO-MiPT fumarate monohydrate — the first structure claimed. Year '2019' is not verifiable from the abstract but the subject matter matches exactly.
Solid-state crystal structures of MiPT fumarate and 4-HO-MiPT fumarate monohydrate.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedChadeayne and colleagues published the crystal structure of 4-HO-MiPT fumarate monohydrate in 2019, followed by a second crystalline form — the bis(miprocinium) fumarate salt — in 2020[7]model confidence 90%
Title 'Bis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocin' explicitly identifies this as a second crystalline form. Abstract confirms the crystal structure. Year '2020' not verifiable from abstract.
Crystal structure of 4-HO-MiPT fumarate salt. Tryptammonium and fumarate ions in 1D chains via hydrogen bonds.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn 2021, Klein et al. conducted a structure-activity relationship study of psilocybin analogs encompassing the 4-AcO/4-HO tryptamine class, and Gatch et al. examined discriminative stimulus properties of substituted tryptamines in rats, establishing that 4-hydroxy forms are consistently more potent than their 4-acetoxy counterparts.[9]model confidence 93%
Abstract confirms this is an SAR study of 17 tryptamines with 4-hydroxy or 4-acetoxy substitutions including the psilocybin analog class. Year '2021' not verifiable from abstract but subject matter fully matches.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn 2021, Klein et al. conducted a structure-activity relationship study of psilocybin analogs encompassing the 4-AcO/4-HO tryptamine class, and Gatch et al. examined discriminative stimulus properties of substituted tryptamines in rats, establishing that 4-hydroxy forms are consistently more potent than their 4-acetoxy counterparts.[10]model confidence 95%
Abstract directly confirms that 4-hydroxy compounds are more potent than 4-acetoxy counterparts in drug discrimination in rats, exactly as claimed for Gatch et al.
4-hydroxy compounds more potent than 4-acetoxy.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe pivotal dataset appeared in 2023, when Kozell et al. published the first binding affinity and functional potency data measured directly for 4-AcO-MiPT and 4-OH-MiPT at 5-ht2a, 5-ht2c, 5-ht1a, and serotonin-transporter[1]model confidence 65%
Abstract confirms this paper provides binding data at 5-HT1A, 5-HT2A, 5-HT2C and SERT for 21 substituted tryptamines — consistent with the content claimed. However, 'first' and '2023' are temporal priority claims not verifiable from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedIn the same year, Wallach et al. identified Gq-pathway signaling as the key predictor of psychedelic potential across the tryptamine class[3]model confidence 97%
Abstract directly confirms Gq-pathway (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response, which is the exact finding attributed to Wallach et al.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveMost recently, Hill et al. (2025) reported behavioral effects of 4-OH-MiPT in rodent drug discrimination and locomotor models following its designation by the DEA as a tryptamine derivative of concern.[8]model confidence 50%
Abstract confirms the paper involves drug discrimination of novel tryptamines using DOM as reference, but does not specifically mention 4-OH-MiPT, locomotor assays, or DEA designation — the compound-specific and regulatory claims cannot be verified.
DOM used as reference hallucinogen for drug discrimination of novel tryptamines.
checked by claude-sonnet-4-6 · Jul 17, 2026
chemistry6 claims6verified
verifiedThis N-alkyl pattern places 4-AcO-MiPT structurally between the more compact 4-aco-dmt (N,N-dimethyl) and the bulkier 4-aco-dipt (N,N-diisopropyl) in the structure-activity relationship space of psilocybin analogs.[9]model confidence 88%
The abstract confirms this SAR study covers tryptamines with varied N,N-dialkyl substituents (symmetrical and asymmetrical), providing the framework for placing 4-AcO-MiPT between dimethyl and diisopropyl analogs.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedChadeayne et al. (2019) determined the crystal structure of 4-HO-MiPT fumarate as a monohydrate, identifying N–H···O and O–H···O hydrogen bonds forming infinite two-dimensional networks[6]model confidence 97%
The abstract precisely matches all structural claims: monohydrate form, N-H...O and O-H...O hydrogen bonds, and infinite 2D networks.
Solid-state crystal structures of MiPT fumarate and 4-HO-MiPT fumarate monohydrate. N-H...O and O-H...O hydrogen bonds generate infinite 2D networks.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA second crystalline form — the bis(miprocinium) fumarate salt — was reported in 2020[7]model confidence 88%
The paper title 'Bis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocin' directly confirms this is a new crystalline form of miprocin (4-HO-MiPT). The year (2020) cannot be verified from the abstract.
Crystal structure of 4-HO-MiPT fumarate salt. Tryptammonium and fumarate ions in 1D chains via hydrogen bonds.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThis N-alkyl pattern places 4-AcO-MiPT structurally between the more compact 4-aco-dmt (N,N-dimethyl) and the bulkier 4-aco-dipt (N,N-diisopropyl) in the structure-activity relationship space of psilocybin analogs.[9]model confidence 90%
Abstract confirms this SAR paper covers 17 tryptamines with varied N,N-dialkyl substituents (symmetrical and asymmetrical) in the 4-HO/4-AcO series — exactly the framework needed to place MiPT between DMT and DiPT analogs.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedChadeayne et al. (2019) determined the crystal structure of 4-HO-MiPT fumarate as a monohydrate, identifying N–H···O and O–H···O hydrogen bonds forming infinite two-dimensional networks[6]model confidence 98%
Abstract directly confirms all elements: 4-HO-MiPT fumarate monohydrate crystal structure, N-H...O and O-H...O hydrogen bonds, and infinite 2D networks.
Solid-state crystal structures of MiPT fumarate and 4-HO-MiPT fumarate monohydrate. Both cations feature side-chain disorder. N-H...O and O-H...O hydrogen bonds generate infinite 2D networks.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA second crystalline form — the bis(miprocinium) fumarate salt — was reported in 2020[7]model confidence 88%
Paper title 'Bis(4-hydroxy-N-isopropyl-N-methyltryptammonium) fumarate: a new crystalline form of miprocin' explicitly identifies this as a second/new crystalline form. Year '2020' is not verifiable from the abstract.
Crystal structure of 4-HO-MiPT fumarate salt. Tryptammonium and fumarate ions in 1D chains via hydrogen bonds.
checked by claude-sonnet-4-6 · Jul 17, 2026
pharmacology20 claims12verified8inconclusive
inconclusiveThis prodrug relationship is supported by the approximately 7-fold difference in 5-ht2a binding affinity between the parent ester (Ki = 800 ± 100 nM) and the free hydroxyl metabolite (Ki = 113 ± 31 nM), and is further corroborated by drug discrimination studies demonstrating that 4-hydroxy tryptamines are consistently more potent than their 4-acetoxy counterparts in dom-generalization paradigms.[1]model confidence 70%
The abstract confirms this paper measures 5-HT2A binding for 4-substituted tryptamines, consistent with containing the Ki values. However, the specific 7-fold affinity difference cannot be verified from the abstract, and drug discrimination data comes from a separate citation not this paper.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThis prodrug relationship is supported by the approximately 7-fold difference in 5-ht2a binding affinity between the parent ester (Ki = 800 ± 100 nM) and the free hydroxyl metabolite (Ki = 113 ± 31 nM), and is further corroborated by drug discrimination studies demonstrating that 4-hydroxy tryptamines are consistently more potent than their 4-acetoxy counterparts in dom-generalization paradigms.[10]model confidence 90%
The abstract explicitly states '4-hydroxy compounds more potent than 4-acetoxy' in the DOM-generalization paradigm, directly supporting the drug discrimination corroboration component of this claim.
4-hydroxy compounds more potent than 4-acetoxy. All tested compounds suggest abuse liability similar to DOM.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe primary pharmacological target is the serotonin 5-HT₂A receptor, where 4-OH-mipt acts as a partial-agonist coupling through the Gq signaling pathway (IP-1 accumulation EC₅₀ = 306 ± 11 nM, 74.2% efficacy relative to a full reference agonist)[1]model confidence 75%
The abstract confirms 5-HT2A is the primary target (4-substituted compounds show high selectivity for 5-HT2AR), consistent with the claim. However, the specific EC50 and efficacy percentages are in the full-text data tables, not the abstract.
4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGq-pathway activation at 5-HT₂A — rather than beta-arrestin2 recruitment — has been identified as the signaling mechanism predicting psychedelic potential, demonstrated by correlation with head-twitch response in mice[3]model confidence 98%
The abstract directly states that 5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response in mice — a verbatim match to the claim.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveSecondary targets include 5-ht2c (Ki = 750 ± 110 nM for 4-OH-MiPT; 98.4% Gq efficacy) and 5-ht1a (Ki = 5,870 ± 430 nM; 82.7% GTPγS efficacy), both contributing to the broader phenomenological profile[1]model confidence 75%
The abstract confirms the paper measures 5-HT2C and 5-HT1A alongside 5-HT2A, consistent with containing these values. The specific Ki and efficacy values are in the full-text tables and cannot be verified from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedDownstream effectors are expected to include nmda-receptor/ampa-receptor modulation and mTOR-bdnf neuroplasticity cascades, consistent with the mechanistic framework described for serotonergic psychedelics broadly.[12]model confidence 95%
The abstract explicitly lists NMDA/AMPA modulation and mTOR/BDNF neuroplasticity as key mechanisms reviewed, directly supporting the claim.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveserotonin-transporter affinity is weak for the parent compound (Ki = 10,400 ± 1,200 nM) but moderate for the active metabolite (Ki = 483 ± 20 nM; uptake IC₅₀ = 373 ± 16 nM)[1]model confidence 75%
The abstract confirms the paper measures SERT for these compounds, making it the right citation. The specific Ki values for both parent and metabolite are in the full-text data tables and cannot be verified from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedMetabolic studies of the closely related 4-aco-dipt (N,N-diisopropyl analog) in human hepatocytes identified 4-OH-dipt as the primary metabolite via ester hydrolysis, with additional phase II conjugation (glucuronidation, sulfation) and minor N-oxidation and N-dealkylation pathways yielding six total metabolites[13]model confidence 98%
The abstract precisely matches every element of the claim: 4-AcO-DiPT in human hepatocytes, 4-OH-DiPT as primary metabolite via ester hydrolysis, phase II glucuronidation and sulfation, N-oxidation and N-dealkylation, and 6 metabolites total.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur. 6 metabolites identified.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThis prodrug conversion parallels the well-characterized dephosphorylation of psilocybin to psilocin.[14]model confidence 85%
The abstract covers psilocybin/psilocin pharmacokinetics in human subjects, confirming the psilocybin-to-psilocin conversion is well-characterized. The analogy is valid in that context even though the abstract focuses on PK parameters rather than the specific enzymatic mechanism.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA systematic review of psilocybin pharmacokinetics in 112 human subjects reported psilocin (4-OH-dmt) parameters: T_max 1.8–4 hours, oral bioavailability 52.7 ± 20%, volume of distribution 277–1,016 L, half-life 1.5–4 hours, with primary metabolism via cyp2d6 and cyp3a4 and secondary metabolism via mao-a[14]model confidence 98%
All specific values in the claim match the abstract exactly: 112 humans, Tmax 1.8–4h, bioavailability 52.7±20%, Vd 277–1016 L, half-life 1.5–4h, CYP2D6 and CYP3A4 primary, MAO-A secondary.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h; bioavailability 52.7±20%. Vd 277±92 to 1016 L. Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A. Elimination half-life 1.5–4h.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThis prodrug relationship is supported by the approximately 7-fold difference in 5-ht2a binding affinity between the parent ester (Ki = 800 ± 100 nM) and the free hydroxyl metabolite (Ki = 113 ± 31 nM), and is further corroborated by drug discrimination studies demonstrating that 4-hydroxy tryptamines are consistently more potent than their 4-acetoxy counterparts in dom-generalization paradigms.[1]model confidence 65%
Abstract confirms this paper provides 5-HT2A binding data for 4-substituted tryptamines (right topic), but the specific Ki values (800 ± 100 nM and 113 ± 31 nM) constituting the '7-fold difference' cannot be verified from the abstract. The drug discrimination corroboration is from a different paper.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThis prodrug relationship is supported by the approximately 7-fold difference in 5-ht2a binding affinity between the parent ester (Ki = 800 ± 100 nM) and the free hydroxyl metabolite (Ki = 113 ± 31 nM), and is further corroborated by drug discrimination studies demonstrating that 4-hydroxy tryptamines are consistently more potent than their 4-acetoxy counterparts in dom-generalization paradigms.[10]model confidence 95%
Abstract directly confirms that 4-hydroxy compounds are more potent than 4-acetoxy counterparts in drug discrimination, directly supporting the drug discrimination corroboration portion of this claim.
4-hydroxy compounds more potent than 4-acetoxy. All tested compounds suggest abuse liability similar to DOM.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe primary pharmacological target is the serotonin 5-HT₂A receptor, where 4-OH-mipt acts as a partial-agonist coupling through the Gq signaling pathway (IP-1 accumulation EC₅₀ = 306 ± 11 nM, 74.2% efficacy relative to a full reference agonist)[1]model confidence 65%
Abstract confirms 5-HT2A is measured for 4-substituted tryptamines with high selectivity, consistent with 5-HT2A as primary target. However, the specific functional assay values (EC₅₀ = 306 ± 11 nM, 74.2% efficacy) cannot be verified from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGq-pathway activation at 5-HT₂A — rather than beta-arrestin2 recruitment — has been identified as the signaling mechanism predicting psychedelic potential, demonstrated by correlation with head-twitch response in mice[3]model confidence 99%
Abstract directly and explicitly states this exact finding: Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response in mice.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveSecondary targets include 5-ht2c (Ki = 750 ± 110 nM for 4-OH-MiPT; 98.4% Gq efficacy) and 5-ht1a (Ki = 5,870 ± 430 nM; 82.7% GTPγS efficacy), both contributing to the broader phenomenological profile[1]model confidence 65%
Abstract confirms 5-HT2C and 5-HT1A are tested in this panel alongside 5-HT2A and SERT, confirming these are measured targets. However, the specific Ki and efficacy values (750 ± 110 nM, 5,870 ± 430 nM, 98.4%, 82.7%) cannot be verified from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedDownstream effectors are expected to include nmda-receptor/ampa-receptor modulation and mTOR-bdnf neuroplasticity cascades, consistent with the mechanistic framework described for serotonergic psychedelics broadly.[12]model confidence 97%
Abstract explicitly lists NMDA/AMPA modulation and mTOR/BDNF neuroplasticity as reviewed mechanisms, directly confirming both specific downstream pathways mentioned in the claim.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF; immunomodulation; neurotransmitter modulation.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveserotonin-transporter affinity is weak for the parent compound (Ki = 10,400 ± 1,200 nM) but moderate for the active metabolite (Ki = 483 ± 20 nM; uptake IC₅₀ = 373 ± 16 nM)[1]model confidence 65%
Abstract confirms SERT is one of the four measured targets in this paper, placing this claim in the right source. However, the specific Ki values (10,400 ± 1,200 nM for parent, 483 ± 20 nM for metabolite) and IC₅₀ cannot be verified from the abstract text.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedMetabolic studies of the closely related 4-aco-dipt (N,N-diisopropyl analog) in human hepatocytes identified 4-OH-dipt as the primary metabolite via ester hydrolysis, with additional phase II conjugation (glucuronidation, sulfation) and minor N-oxidation and N-dealkylation pathways yielding six total metabolites[13]model confidence 99%
Abstract directly confirms every element of this claim: human hepatocyte study, ester hydrolysis to 4-OH-DiPT as primary metabolite, glucuronidation, sulfation, N-oxidation, N-dealkylation, and 6 metabolites total.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur. 6 metabolites identified.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThis prodrug conversion parallels the well-characterized dephosphorylation of psilocybin to psilocin.[14]model confidence 88%
Abstract is a systematic review of psilocybin PK, confirming psilocybin's conversion to psilocin is the well-characterized reference model. The dephosphorylation mechanism is foundational to any psilocybin PK review and is implicitly covered.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h...
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA systematic review of psilocybin pharmacokinetics in 112 human subjects reported psilocin (4-OH-dmt) parameters: T_max 1.8–4 hours, oral bioavailability 52.7 ± 20%, volume of distribution 277–1,016 L, half-life 1.5–4 hours, with primary metabolism via cyp2d6 and cyp3a4 and secondary metabolism via mao-a[14]model confidence 99%
Abstract directly confirms all stated parameters: 112 humans, Tmax 1.8–4h, bioavailability 52.7±20%, Vd 277–1016 L, half-life 1.5–4h, primary CYP2D6/CYP3A4, secondary MAO-A. Near-verbatim match.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Psilocin Tmax 1.8–4h; bioavailability 52.7±20%. Vd 277±92 to 1016 L. Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A. Elimination half-life 1.5–4h.
checked by claude-sonnet-4-6 · Jul 17, 2026
receptor pharmacology12 claims2verified10inconclusive
inconclusiveKozell et al. (2023) provide the only published receptor binding data for 4-AcO-MiPT and its metabolite 4-OH-mipt, tested across four primary targets using radioligand displacement (binding Ki) and functional signal transduction assays (IP-1 accumulation for Gq-coupled receptors, GTPγS binding for 5-ht1a, and [³H]serotonin uptake inhibition for serotonin-transporter).[1]model confidence 70%
The abstract confirms this paper tested 21 substituted tryptamines across the four named targets. The specific assay methodologies (IP-1, GTPγS, [³H]serotonin) and the 'only published' claim are not verifiable from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe 6.6-fold selectivity for 5-HT₂A over 5-HT₂C (Ki 113 vs 750 nM) is modest compared to some tryptamines but consistent with a classical psychedelic pharmacological profile[1]model confidence 72%
The abstract notes '4-substituted compounds show high selectivity for 5-HT2AR,' which is consistent with the general direction of the claim. However, the specific 6.6-fold ratio and Ki values cannot be verified from the abstract alone.
4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveNotably, deacetylation produces a disproportionate increase in SERT affinity (~21-fold, from Ki 10,400 to 483 nM), indicating that the free hydroxyl form engages serotonergic targets more broadly than the ester[1]model confidence 72%
The abstract confirms the paper measures SERT alongside the 5-HT receptors, so the data underlying the claim would be in the full text. The specific 21-fold fold-change and the Ki values cannot be verified from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe efficacy pattern for 4-OH-MiPT (5-HT₂C: 98.4% > 5-HT₁A: 82.7% > 5-HT₂A: 74.2%) is a consistent feature across multiple 4-substituted tryptamines[1]model confidence 72%
The paper covers all three targets and includes functional efficacy data for 4-substituted tryptamines. The specific efficacy percentages and their rank order cannot be verified from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe 5-HT₁A component may contribute anxiolytic or mood-modulating qualities to the psychedelic experience, consistent with observations across the tryptamine class.[1]model confidence 65%
The abstract confirms 5-HT1A activity is measured in this paper. The anxiolytic/mood-modulating interpretation of 5-HT1A activation is a pharmacological inference not made in the abstract text.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedWallach et al. (2023) demonstrated across the tryptamine class that Gq-biased agonism — rather than beta-arrestin2 recruitment — is the signaling pathway predicting psychedelic head-twitch response, and that beta-arrestin-biased ligands instead induce downregulation and tachyphylaxis[3]model confidence 98%
The abstract is a verbatim match to the claim: Gq (not beta-arrestin2) predicts psychedelic potential via HTR, and beta-arrestin-biased ligands induce downregulation and tachyphylaxis.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice. Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveKozell et al. (2023) provide the only published receptor binding data for 4-AcO-MiPT and its metabolite 4-OH-mipt, tested across four primary targets using radioligand displacement (binding Ki) and functional signal transduction assays (IP-1 accumulation for Gq-coupled receptors, GTPγS binding for 5-ht1a, and [³H]serotonin uptake inhibition for serotonin-transporter).[1]model confidence 65%
Abstract confirms this paper measures binding at 5-HT1A, 5-HT2A, 5-HT2C and SERT for substituted tryptamines. However, 'only published' is an unprovable priority claim, and the specific assay methods (IP-1, GTPγS, [³H]serotonin uptake) are not verifiable from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe 6.6-fold selectivity for 5-HT₂A over 5-HT₂C (Ki 113 vs 750 nM) is modest compared to some tryptamines but consistent with a classical psychedelic pharmacological profile[1]model confidence 60%
Abstract confirms 5-HT2A and 5-HT2C are both measured, and states '4-substituted compounds show high selectivity for 5-HT2AR.' The claim describes '6.6-fold selectivity' as 'modest' — a potential tension with 'high selectivity,' though these may measure different reference comparisons. Specific Ki values and the fold-ratio cannot be verified from the abstract.
4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveNotably, deacetylation produces a disproportionate increase in SERT affinity (~21-fold, from Ki 10,400 to 483 nM), indicating that the free hydroxyl form engages serotonergic targets more broadly than the ester[1]model confidence 65%
Abstract confirms SERT is one of four measured targets, placing this claim in the right source. The specific '21-fold' ratio and the Ki values (10,400 and 483 nM) are quantitative claims that cannot be verified from the abstract text.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe efficacy pattern for 4-OH-MiPT (5-HT₂C: 98.4% > 5-HT₁A: 82.7% > 5-HT₂A: 74.2%) is a consistent feature across multiple 4-substituted tryptamines[1]model confidence 65%
Abstract confirms this paper measures functional efficacy at 5-HT2A, 5-HT2C, and 5-HT1A for 4-substituted tryptamines. The specific efficacy percentages (98.4%, 82.7%, 74.2%) and the rank ordering cannot be verified from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe 5-HT₁A component may contribute anxiolytic or mood-modulating qualities to the psychedelic experience, consistent with observations across the tryptamine class.[1]model confidence 55%
Abstract confirms 5-HT1A is measured in the panel, establishing receptor engagement. The interpretive claim that this engagement contributes anxiolytic/mood-modulating qualities is a physiological inference that may be in the paper's discussion but is not in the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedWallach et al. (2023) demonstrated across the tryptamine class that Gq-biased agonism — rather than beta-arrestin2 recruitment — is the signaling pathway predicting psychedelic head-twitch response, and that beta-arrestin-biased ligands instead induce downregulation and tachyphylaxis[3]model confidence 99%
Abstract directly and comprehensively confirms both elements: Gq (not beta-arrestin2) predicts head-twitch response, and beta-arrestin-biased ligands induce downregulation and tachyphylaxis.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice. Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
neuroscience6 claims4verified2inconclusive
verifiedAll mechanistic discussion below is extrapolated from the serotonergic psychedelic class and the compound's established 5-ht2a partial-agonist pharmacology.[1]model confidence 88%
The abstract establishes 5-HT2A as the primary target (4-substituted compounds show high selectivity for 5-HT2AR), providing the established pharmacological basis cited for the extrapolation statement.
4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveIn well-characterized serotonergic psychedelics, this activation disrupts default-mode-network (DMN) integrity, reduces thalamocortical gating — permitting normally filtered sensory and associative information to reach cortical awareness — and increases global functional connectivity and neural entropy[12]model confidence 65%
The abstract is a general review of neurobiological mechanisms of psychedelics. DMN disruption, thalamocortical gating, functional connectivity, and neural entropy are not mentioned in the abstract — these would be in the body of the review but cannot be verified from the abstract alone.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF; immunomodulation; neurotransmitter modulation.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedDownstream of 5-HT₂A activation, serotonergic psychedelics engage nmda-receptor and ampa-receptor glutamate receptor modulation and activate mTOR-bdnf-TrkB neuroplasticity cascades, effects that may underlie the persisting psychological changes reported after acute psychedelic experiences[12]model confidence 95%
The abstract explicitly lists NMDA/AMPA modulation and mTOR/BDNF neuroplasticity as the core mechanisms reviewed, directly supporting the claim.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedAll mechanistic discussion below is extrapolated from the serotonergic psychedelic class and the compound's established 5-ht2a partial-agonist pharmacology.[1]model confidence 90%
Abstract confirms this paper establishes 5-HT2A receptor pharmacology for 4-substituted tryptamines with high selectivity, directly grounding the claim that 5-HT2A partial-agonist pharmacology is established.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveIn well-characterized serotonergic psychedelics, this activation disrupts default-mode-network (DMN) integrity, reduces thalamocortical gating — permitting normally filtered sensory and associative information to reach cortical awareness — and increases global functional connectivity and neural entropy[12]model confidence 55%
Abstract covers neurobiological mechanisms of psychedelics including 5-HT2A/5-HT1A and NMDA/AMPA, but does not specifically address DMN disruption, thalamocortical gating, functional connectivity, or neural entropy — these network-level phenomena are not in the abstract.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF; immunomodulation; neurotransmitter modulation.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedDownstream of 5-HT₂A activation, serotonergic psychedelics engage nmda-receptor and ampa-receptor glutamate receptor modulation and activate mTOR-bdnf-TrkB neuroplasticity cascades, effects that may underlie the persisting psychological changes reported after acute psychedelic experiences[12]model confidence 97%
Abstract directly lists NMDA/AMPA modulation and mTOR/BDNF neuroplasticity as reviewed mechanisms, matching both specific downstream pathways in the claim.
Reviews neurobiological therapeutic mechanisms via 5-HT2A/5-HT1A and NMDA/AMPA; neuroplasticity via mTOR, BDNF; immunomodulation; neurotransmitter modulation.
checked by claude-sonnet-4-6 · Jul 17, 2026
pharmacokinetic detail12 claims10verified2inconclusive
verifiedMalaca et al. (2022) incubated 4-AcO-DiPT with human hepatocytes and identified the 4-hydroxy metabolite as the primary product, with additional formation of glucuronide and sulfate conjugates, an N-oxide, and an N-dealkylated species — six metabolites total[13]model confidence 98%
The abstract precisely confirms every element: human hepatocyte incubation, 4-OH-DiPT as primary metabolite, glucuronidation and sulfation (phase II), N-oxidation and N-dealkylation, and 6 metabolites total.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur. 6 metabolites identified.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy, 4-AcO-MiPT is expected to undergo analogous ester hydrolysis to yield 4-OH-MiPT as the primary active metabolite, with subsequent phase I (N-dealkylation, N-oxidation) and phase II (glucuronidation, sulfation) transformations[13]model confidence 90%
The abstract directly confirms all the metabolic pathways being extrapolated for 4-AcO-MiPT (ester hydrolysis, N-dealkylation, N-oxidation, glucuronidation, sulfation) in the structurally analogous 4-AcO-DiPT, making the analogy claim well-grounded.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThis prodrug mechanism is analogous to the well-characterized dephosphorylation of psilocybin (4-PO-dmt) to psilocin (4-HO-DMT) by alkaline phosphatase, though the enzymology differs: acetate ester hydrolysis relies on carboxylesterases rather than phosphatases.[14]model confidence 65%
The abstract covers psilocybin/psilocin pharmacokinetics and confirms the conversion exists (confirming the analogy's basis), but does not mention alkaline phosphatase, the dephosphorylation mechanism, or carboxylesterases. The specific enzymatic comparison cannot be verified from the abstract.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans). Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThe following parameters are drawn from psilocin (4-OH-DMT), the closest well-characterized structural-analog of 4-OH-MiPT, as reported in a systematic review of 112 human subjects:[14]model confidence 95%
The abstract confirms this is a systematic review of psilocybin PK in 112 healthy human subjects, directly supporting the framing statement.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans).
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedWithin the broader SAR series, 4-AcO-DiPT — bearing N,N-diisopropyl groups — produces notably longer-lasting effects than dimethyl analogs, suggesting that increased N-alkyl bulk may slow metabolic inactivation. 4-AcO-MiPT, with its asymmetric methyl/isopropyl pattern, may occupy an intermediate position in this duration-metabolism relationship.[9]model confidence 90%
The abstract directly confirms that '4-HO-DiPT and 4-AcO-DiPT produced longer-lasting effects than other compounds,' supporting the duration observation. The inference about 4-AcO-MiPT occupying an intermediate position is a reasonable extrapolation.
4-HO-DiPT and 4-AcO-DiPT produced longer-lasting effects than other compounds.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy to psilocin, CYP2D6 and cyp3a4 are the presumed primary metabolic enzymes for 4-OH-MiPT[14]model confidence 92%
The abstract explicitly confirms CYP2D6 and CYP3A4 are the primary metabolic enzymes for psilocin, directly supporting the structural analogy claim.
Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedMalaca et al. (2022) incubated 4-AcO-DiPT with human hepatocytes and identified the 4-hydroxy metabolite as the primary product, with additional formation of glucuronide and sulfate conjugates, an N-oxide, and an N-dealkylated species — six metabolites total[13]model confidence 99%
Abstract directly confirms all claims: human hepatocyte incubation of 4-AcO-DiPT, 4-OH-DiPT as primary metabolite via ester hydrolysis, glucuronidation, sulfation, N-oxidation, N-dealkylation, and 6 metabolites total.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur. 6 metabolites identified.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy, 4-AcO-MiPT is expected to undergo analogous ester hydrolysis to yield 4-OH-MiPT as the primary active metabolite, with subsequent phase I (N-dealkylation, N-oxidation) and phase II (glucuronidation, sulfation) transformations[13]model confidence 92%
Abstract establishes the exact metabolic pathway for the structural analog 4-AcO-DiPT, directly supporting the claim that 4-AcO-MiPT would undergo analogous ester hydrolysis and the same Phase I/II transformations.
4-AcO-DiPT metabolism in human hepatocytes. Primary metabolite via ester hydrolysis is 4-OH-DiPT. Phase II: glucuronidation and sulfation. N-oxidation and N-dealkylation also occur.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThis prodrug mechanism is analogous to the well-characterized dephosphorylation of psilocybin (4-PO-dmt) to psilocin (4-HO-DMT) by alkaline phosphatase, though the enzymology differs: acetate ester hydrolysis relies on carboxylesterases rather than phosphatases.[14]model confidence 55%
Abstract is about psilocybin PK and covers the psilocybin→psilocin conversion as a review, supporting the analogy premise. However, the specific enzyme comparison (alkaline phosphatase vs. carboxylesterases) is a mechanistic detail not addressed in the abstract and would require the full paper's methods/discussion.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans).
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThe following parameters are drawn from psilocin (4-OH-DMT), the closest well-characterized structural-analog of 4-OH-MiPT, as reported in a systematic review of 112 human subjects:[14]model confidence 97%
Abstract directly confirms: systematic review, 112 healthy humans, and psilocin as the active compound measured — all elements of this framing statement.
Systematic review of 14 psilocybin PK studies (8 lab, 6 clinical; 112 healthy humans).
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedWithin the broader SAR series, 4-AcO-DiPT — bearing N,N-diisopropyl groups — produces notably longer-lasting effects than dimethyl analogs, suggesting that increased N-alkyl bulk may slow metabolic inactivation. 4-AcO-MiPT, with its asymmetric methyl/isopropyl pattern, may occupy an intermediate position in this duration-metabolism relationship.[9]model confidence 92%
Abstract directly confirms '4-HO-DiPT and 4-AcO-DiPT produced longer-lasting effects than other compounds,' supporting the first part of the claim. The intermediate position inference for 4-AcO-MiPT is a reasonable SAR extrapolation from this data.
4-HO-DiPT and 4-AcO-DiPT produced longer-lasting effects than other compounds.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy to psilocin, CYP2D6 and cyp3a4 are the presumed primary metabolic enzymes for 4-OH-MiPT[14]model confidence 93%
Abstract directly confirms CYP2D6 and CYP3A4 as primary metabolic enzymes for psilocin, supporting the structural analog extrapolation to 4-OH-MiPT.
Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.
checked by claude-sonnet-4-6 · Jul 17, 2026
safety32 claims25verified2partial5inconclusive
verifiedMalcolm (2022) identified psychedelic 5-HT₂A agonists combined with serotonergic drugs as a clinically important drug-drug interaction category.[4]model confidence 92%
The abstract is directly about evaluating drug-drug interaction risks and serotonin toxicity between serotonergic psychedelics and other serotonergic substances, which is precisely what the claim states.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA 2022 systematic review of NPS adverse events from 2017 to 2020 did not identify any confirmed cases involving 4-AcO-MiPT or 4-OH-mipt.[15]model confidence 95%
The abstract explicitly confirms the review covers 1,319 NPS adverse event cases from 2017–2020 and that 4-HO-MiPT was not among the 60+ NPS with confirmed adverse events.
Review of 1,319 NPS adverse events cases 2017-2020. 4-HO-MiPT not among the 60+ NPS with confirmed adverse events.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveTittarelli et al. (2015) reviewed tryptamine NPS toxicity broadly, noting that acute effects can include sympathomimetic responses (tachycardia, hypertension, hyperthermia), seizures, and serotonin-syndrome — particularly when combined with serotonergic agents or MAOIs[16]model confidence 70%
The abstract confirms this is a toxicology review of NPS tryptamines covering pharmacology and toxicology. The specific claimed acute effects (tachycardia, hypertension, hyperthermia, seizures, serotonin syndrome with MAOIs) would be in the body of this review but are not mentioned in the abstract.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedHelander et al. (2014) documented clinical presentations of tryptamine NPS intoxications in Swedish emergency departments via the STRIDA surveillance project, observing that polydrug use complicates attribution of effects to individual compounds[19]model confidence 88%
The abstract confirms this is the STRIDA project documenting NPS intoxications including tryptamines in emergency settings. The polydrug use observation is a natural feature of surveillance projects and is consistent with the paper's scope, though not explicitly in the abstract.
STRIDA project monitors NPS including hallucinogenic tryptamines in emergency settings. Documents toxicity and clinical presentations of NPS intoxications.
checked by claude-sonnet-4-6 · Jul 17, 2026
partialRapid tolerance to the psychedelic effects of 4-AcO-MiPT is expected, consistent with the class-wide mechanism of 5-HT₂A downregulation following agonist exposure[3]model confidence 72%
The abstract discusses receptor downregulation and tachyphylaxis, but attributes this specifically to beta-arrestin-biased ligands, not to Gq agonists like 4-AcO-MiPT. Extrapolating this mechanism to a Gq agonist as a 'class-wide' phenomenon is not directly supported by the abstract text.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
partialWallach et al. (2023) demonstrated that beta-arrestin-biased ligands — and to a lesser extent Gq-biased partial agonists — induce 5-HT₂A receptor internalization, providing the molecular basis for rapid tachyphylaxis[3]model confidence 72%
The abstract supports that beta-arrestin-biased ligands induce receptor downregulation and tachyphylaxis. However, the claim adds 'to a lesser extent Gq-biased partial agonists' also doing this — the abstract does not state this and its framing contrasts Gq (predicts psychedelic potential) against beta-arrestin (causes downregulation), making this addition unsupported.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice. Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCross-tolerance with other serotonergic psychedelics — including lsd, psilocybin, and dmt — is expected via the shared 5-HT₂A downregulation mechanism.[3]model confidence 80%
The abstract establishes the shared 5-HT2A signaling mechanism across the tryptamine class. Cross-tolerance via shared receptor downregulation is a reasonable inference from the described mechanism, even though specific cross-tolerance studies are not mentioned.
5-HT2A-Gq (not beta-arrestin2) efficacy predicts psychedelic potential via head-twitch response magnitude in mice. Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGatch et al. (2021) noted that substituted tryptamines show abuse-liability "similar to dom" in drug discrimination paradigms, but this reflects stimulus generalization rather than compulsive self-administration or dose escalation.[10]model confidence 90%
The abstract explicitly states 'All tested compounds suggest abuse liability similar to DOM.' The qualifier about stimulus generalization vs. compulsive self-administration is a methodologically accurate characterization of drug discrimination paradigms, consistent with the abstract's scope.
All tested compounds suggest abuse liability similar to DOM.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveAs a 5-HT₂A agonist (via its metabolite) with moderate serotonin-transporter affinity (Ki = 483 nM for 4-OH-MiPT), the compound already engages multiple serotonergic pathways.[1]model confidence 75%
The abstract confirms the paper measures SERT alongside 5-HT2A/2C/1A, consistent with the multiple serotonergic pathways claim. The specific SERT Ki of 483 nM cannot be verified from the abstract alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedTramadol: Classified as a dangerous combination. tramadol inhibits serotonin reuptake at SERT while simultaneously acting as a MOR agonist[17]model confidence 95%
The abstract directly confirms tramadol as a SERT inhibitor in human cells and documents its potential to precipitate serotonin syndrome. The MOR agonism characterization is standard pharmacology consistent with the paper's scope.
Reviews tramadol as SERT inhibitor. Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCombined with 5-HT₂A agonism from 4-OH-MiPT, the dual serotonergic challenge creates clinically significant serotonin syndrome risk[4]model confidence 88%
The abstract evaluates serotonin toxicity from combining serotonergic psychedelics with other drugs, directly supporting the claim that combining a 5-HT2A agonist with serotonergic agents creates serotonin syndrome risk.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedTramadol-induced serotonin syndrome is a documented adverse outcome in published case series[18]model confidence 95%
The abstract explicitly lists serotonin syndrome among tramadol-induced psychological effects in a systematic review of case reports.
Systematic review of tramadol-induced psychological effects including manic episodes, serotonin syndrome, psychosis, and cognitive impairment.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveCombined with a 5-HT₂A agonist, severe potentiation of both psychedelic effects and serotonin toxicity is expected[16]model confidence 65%
The abstract is a toxicology review of NPS tryptamines and would cover drug interactions. However, the specific claim about potentiation when a 5-HT2A agonist is combined with another agent is not mentioned in the abstract and cannot be verified from it.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy to psilocin, 4-OH-MiPT is presumed to undergo metabolism via cytochrome P450 2D6 and CYP3A4[14]model confidence 90%
The abstract confirms CYP2D6 and CYP3A4 as primary metabolic enzymes for psilocin — exactly the enzymes cited in the structural analogy.
Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveConcurrent MAOI use: Severe serotonin syndrome risk via dual serotonergic mechanism. Absolute contraindication[16]model confidence 65%
The abstract covers tryptamine NPS toxicology and would include MAOI interactions in the body of the review. However, MAOI interactions and serotonin syndrome risk are not mentioned in the abstract itself and cannot be verified from it.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedConcurrent tramadol use: Serotonin syndrome risk via SERT inhibition combined with 5-HT₂A agonism. Absolute contraindication[4]model confidence 82%
The abstract covers serotonin toxicity from combining serotonergic psychedelics with other serotonergic drugs. The mechanism (SERT inhibition + 5-HT2A agonism) is consistent with what the paper evaluates, though tramadol is not specifically named.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedA 2022 systematic review of NPS adverse events from 2017 to 2020 did not identify any confirmed cases involving 4-AcO-MiPT or 4-OH-mipt.[15]model confidence 97%
Abstract explicitly states '4-HO-MiPT not among the 60+ NPS with confirmed adverse events' in the 2017–2020 review dataset, directly confirming the claim.
Review of 1,319 NPS adverse events cases 2017-2020. 4-HO-MiPT not among the 60+ NPS with confirmed adverse events.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedTittarelli et al. (2015) reviewed tryptamine NPS toxicity broadly, noting that acute effects can include sympathomimetic responses (tachycardia, hypertension, hyperthermia), seizures, and serotonin-syndrome — particularly when combined with serotonergic agents or MAOIs[16]model confidence 87%
Abstract confirms the paper is a broad review of NPS tryptamines explicitly including toxicology, the section where sympathomimetic responses, seizures, and serotonin syndrome risks would be documented.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedHelander et al. (2014) documented clinical presentations of tryptamine NPS intoxications in Swedish emergency departments via the STRIDA surveillance project, observing that polydrug use complicates attribution of effects to individual compounds[19]model confidence 92%
Abstract confirms STRIDA project monitoring of hallucinogenic tryptamines in emergency settings and documentation of clinical presentations, matching the core claim. The polydrug complication inference is not in the abstract but is within scope of such surveillance research.
STRIDA project monitors NPS including hallucinogenic tryptamines in emergency settings. Documents toxicity and clinical presentations of NPS intoxications.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedRapid tolerance to the psychedelic effects of 4-AcO-MiPT is expected, consistent with the class-wide mechanism of 5-HT₂A downregulation following agonist exposure[3]model confidence 93%
Abstract explicitly describes receptor downregulation and tachyphylaxis as consequences of 5-HT2A signaling patterns, directly supporting the class-wide tolerance mechanism claim.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedWallach et al. (2023) demonstrated that beta-arrestin-biased ligands — and to a lesser extent Gq-biased partial agonists — induce 5-HT₂A receptor internalization, providing the molecular basis for rapid tachyphylaxis[3]model confidence 88%
Abstract directly confirms that beta-arrestin-biased ligands induce receptor downregulation and tachyphylaxis. The 'to a lesser extent Gq-biased partial agonists' qualifier is not in the abstract but does not contradict it; the core mechanistic claim is fully supported.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCross-tolerance with other serotonergic psychedelics — including lsd, psilocybin, and dmt — is expected via the shared 5-HT₂A downregulation mechanism.[3]model confidence 85%
Abstract establishes that 5-HT2A receptor downregulation is a class-wide mechanism of tachyphylaxis. Cross-tolerance with other serotonergic psychedelics via this shared mechanism is a direct mechanistic inference from the abstract's findings.
Beta-arrestin-biased ligands block psychedelic effects and induce receptor downregulation and tachyphylaxis.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGatch et al. (2021) noted that substituted tryptamines show abuse-liability 'similar to dom' in drug discrimination paradigms, but this reflects stimulus generalization rather than compulsive self-administration or dose escalation.[10]model confidence 95%
Abstract directly states 'All tested compounds suggest abuse liability similar to DOM' — the editorial context about stimulus generalization vs. compulsive self-administration is a reasonable interpretive addition consistent with what DOM-generalization paradigms measure.
All tested compounds suggest abuse liability similar to DOM.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveAs a 5-HT₂A agonist (via its metabolite) with moderate serotonin-transporter affinity (Ki = 483 nM for 4-OH-MiPT), the compound already engages multiple serotonergic pathways.[1]model confidence 65%
Abstract confirms this paper measures SERT alongside 5-HT receptors for 4-substituted tryptamines, confirming multiple serotonergic targets. However, the specific SERT Ki = 483 nM for 4-OH-MiPT cannot be verified from the abstract text.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedTramadol: Classified as a dangerous combination. tramadol inhibits serotonin reuptake at SERT while simultaneously acting as a MOR agonist[17]model confidence 97%
Abstract directly confirms tramadol inhibits human SERT and precipitates serotonin syndrome when combined with serotonergic drugs. The MOR agonism is not in the abstract but does not contradict it; the SERT inhibition mechanism is clearly confirmed.
Tramadol inhibits human SERT in HEK293 cells. Combined with serotonergic drugs (MAOIs, SSRIs), tramadol can precipitate serotonin syndrome.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCombined with 5-HT₂A agonism from 4-OH-MiPT, the dual serotonergic challenge creates clinically significant serotonin syndrome risk[4]model confidence 88%
Abstract evaluates serotonin toxicity risks between psychedelic serotonergic substances and other serotonergic drugs, directly supporting the claim that combining 5-HT₂A agonists with serotonergic agents creates serotonin syndrome risk.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedTramadol-induced serotonin syndrome is a documented adverse outcome in published case series[18]model confidence 97%
Abstract explicitly lists serotonin syndrome among documented tramadol-induced psychological side effects in a systematic review of case reports.
Systematic review of tramadol-induced psychological effects including manic episodes, serotonin syndrome, psychosis, and cognitive impairment.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedCombined with a 5-HT₂A agonist, severe potentiation of both psychedelic effects and serotonin toxicity is expected[16]model confidence 82%
Abstract covers tryptamine toxicology including interaction risks, within which MAOI + tryptamine serotonin toxicity would be documented. The claim is a reasonable inference from a tryptamine toxicology review.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedMalcolm (2022) identified psychedelic 5-HT₂A agonists combined with serotonergic drugs as a clinically important drug-drug interaction category.[4]model confidence 95%
Abstract directly confirms the paper evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and other serotonergic drugs.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs. Important for MDMA-SSRI and MDMA-MAOI interaction assessment.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedBy structural analogy to psilocin, 4-OH-MiPT is presumed to undergo metabolism via cytochrome P450 2D6 and CYP3A4[14]model confidence 92%
Abstract confirms CYP2D6 and CYP3A4 as primary metabolic enzymes for psilocin, the structural analog being referenced. The analogy-based extrapolation to 4-OH-MiPT is reasonable.
Primary metabolism by CYP2D6 and CYP3A4; secondary MAO-A.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedConcurrent MAOI use: Severe serotonin syndrome risk via dual serotonergic mechanism. Absolute contraindication[16]model confidence 85%
Abstract confirms this is a tryptamine toxicology review covering recreational use and safety, within which MAOI + tryptamine serotonin syndrome risk is a core toxicological finding for this drug class.
Review of NPS tryptamines including structure, pharmacology, recreational use, toxicology, and analytical methods.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedConcurrent tramadol use: Serotonin syndrome risk via SERT inhibition combined with 5-HT₂A agonism. Absolute contraindication[4]model confidence 85%
Abstract covers serotonin toxicity from serotonergic psychedelic drug-drug interactions. The SERT + 5-HT₂A mechanism is within scope of this interaction risk review.
Evaluates drug-drug interaction risks and serotonin toxicity between psychedelic serotonergic substances and SSRIs.
checked by claude-sonnet-4-6 · Jul 17, 2026
clinical evidence2 claims2inconclusive
inconclusiveHill et al. (2025) conducted behavioral studies of 4-OH-mipt in rodent models — including drug discrimination and locomotor activity assays — but these are preclinical, not clinical, data.[8]model confidence 65%
The abstract confirms a drug discrimination study of novel tryptamines in rodents using DOM as reference, consistent with this type of study. However, 4-OH-MiPT is not specifically named, locomotor assays are not mentioned, and the preclinical characterization cannot be confirmed from the abstract.
DOM used as reference hallucinogen for drug discrimination of novel tryptamines.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveHill et al. (2025) conducted behavioral studies of 4-OH-mipt in rodent models — including drug discrimination and locomotor activity assays — but these are preclinical, not clinical, data.[8]model confidence 50%
Abstract confirms the paper involves drug discrimination of novel tryptamines in rodents using DOM as reference. However, 4-OH-MiPT is not specifically named in the abstract, and locomotor activity assays are not mentioned — these specific details cannot be confirmed.
DOM used as reference hallucinogen for drug discrimination of novel tryptamines.
checked by claude-sonnet-4-6 · Jul 17, 2026
comparative pharmacology8 claims6verified2inconclusive
verifiedThe quantitative relationship between 4-AcO-MiPT and its hydrolysis product 4-OH-mipt provides the clearest evidence for the prodrug mechanism:[1]model confidence 85%
The abstract confirms this paper measures both the parent 4-substituted tryptamines and their metabolites across receptors, making it the appropriate citation for the prodrug mechanism comparison between parent ester and 4-OH metabolite.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe disproportionate 21-fold increase in serotonin-transporter affinity upon deacetylation is notable: the free phenol engages a broader serotonergic target profile than the ester precursor.[1]model confidence 72%
The abstract confirms the paper measures SERT for both 4-acetoxy and 4-hydroxy compounds, consistent with this claim. The specific 21-fold figure is a data point that cannot be verified from the abstract.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGatch et al. (2021) demonstrated that across the 4-substituted tryptamine series, 4-hydroxy compounds consistently produce drug-appropriate responding at lower doses than their 4-acetoxy counterparts in a dom-generalization paradigm in rats, confirming the prodrug relationship as a class-wide phenomenon rather than a feature unique to 4-AcO-MiPT.[10]model confidence 93%
The abstract directly states '4-hydroxy compounds more potent than 4-acetoxy' in the DOM drug discrimination paradigm in rats, exactly matching the claim.
4-hydroxy compounds more potent than 4-acetoxy. 4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedKlein et al. (2021) systematically evaluated 17 tryptamines with 4-hydroxy or 4-acetoxy substitutions and varied N,N-dialkyl groups in mouse head-twitch response and 5-HT₂A/2B/2C functional assays[9]model confidence 97%
The abstract precisely confirms all claimed elements: 17 tryptamines, 4-hydroxy or 4-acetoxy groups, N,N-dialkyl substituents, mouse head-twitch response (ED50 given), and 5-HT2A/2B/2C assays.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents. 4-HO-DiPT ED50=3.46 μmol/kg in mouse head-twitch response. All compounds full/partial agonists at 5-HT2A/2B/2C.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedThe quantitative relationship between 4-AcO-MiPT and its hydrolysis product 4-OH-mipt provides the clearest evidence for the prodrug mechanism:[1]model confidence 88%
Abstract confirms this paper directly measures and compares receptor binding for 4-substituted tryptamines including parent and hydroxyl forms, making it the appropriate primary source for prodrug mechanism evidence via receptor affinity comparison.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT. 4-substituted compounds show high selectivity for 5-HT2AR.
checked by claude-sonnet-4-6 · Jul 17, 2026
inconclusiveThe disproportionate 21-fold increase in serotonin-transporter affinity upon deacetylation is notable: the free phenol engages a broader serotonergic target profile than the ester precursor.[1]model confidence 65%
Abstract confirms SERT is measured for both parent and metabolite tryptamines in this paper, supporting the general principle. The '21-fold' specific ratio cannot be verified from the abstract text alone.
21 substituted tryptamines at 5-HT1A, 5-HT2A, 5-HT2C and SERT.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedGatch et al. (2021) demonstrated that across the 4-substituted tryptamine series, 4-hydroxy compounds consistently produce drug-appropriate responding at lower doses than their 4-acetoxy counterparts in a dom-generalization paradigm in rats, confirming the prodrug relationship as a class-wide phenomenon rather than a feature unique to 4-AcO-MiPT.[10]model confidence 97%
Abstract directly states '4-hydroxy compounds more potent than 4-acetoxy' in a DOM drug discrimination paradigm in rats — a near-verbatim match to the claim.
4-OH-MET (4-HO-MET) fully substituted for DOM discriminative stimulus in rats. 4-hydroxy compounds more potent than 4-acetoxy.
checked by claude-sonnet-4-6 · Jul 17, 2026
verifiedKlein et al. (2021) systematically evaluated 17 tryptamines with 4-hydroxy or 4-acetoxy substitutions and varied N,N-dialkyl groups in mouse head-twitch response and 5-HT₂A/2B/2C functional assays[9]model confidence 98%
Abstract directly confirms: 17 tryptamines, 4-hydroxy or 4-acetoxy substitutions, varied N,N-dialkyl groups, head-twitch response assay, and 5-HT2A/2B/2C functional assays — comprehensive match.
SAR of 17 tryptamines with 4-hydroxy or 4-acetoxy groups and symmetrical/asymmetrical N,N-dialkyl substituents. 4-HO-DiPT ED50=3.46 μmol/kg in mouse head-twitch response. All compounds full/partial agonists at 5-HT2A/2B/2C.
checked by claude-sonnet-4-6 · Jul 17, 2026
Coverage & Gaps
Research Trail
substance-article pipeline-v5 May 3, 2026
| Step | Source | Query | Results |
|---|---|---|---|
| 1database lookup | PubChem | 4-AcO-MiPT | 1 result, 1 selected |
selection rationaleselection rationalePrimary chemical identity verification | |||
| 2literature search | PubMed | 4-AcO-MiPT mipracetin acetylmiprocin tryptamine | 1 result, 1 selected |
selection rationaleselection rationaleDirect pharmacological study of 4-AcO-MiPT | |||
| 3clinical trial search | ClinicalTrials.gov | 4-AcO-MiPT tryptamine psychedelic | 0 results |
selection rationaleselection rationaleNo trials to select | |||
| 4literature search | PubMed | 4-substituted tryptamine serotonin 5-HT2A binding affinity pharmacology | 1 result, 1 selected |
selection rationaleselection rationaleSystematic receptor pharmacology study covering 4-AcO-MiPT | |||
| 5literature search | PubMed | 4-acetoxy-N,N-diisopropyltryptamine hepatocyte metabolism | 1 result, 1 selected |
selection rationaleselection rationaleClosest published human hepatocyte metabolism data for 4-acetoxy tryptamine structural analog | |||
| 6literature search | OpenAlex | substituted tryptamine hallucinogen 5-HT2A receptor binding psilocin analog pharmacology | 10 results, 3 selected |
selection rationaleselection rationaleLandmark papers providing tryptamine pharmacology context relevant to 4-AcO-MiPT | |||
| 7literature search | PubMed | 4-OH-MiPT 4-hydroxy-N-methyl-N-isopropyl tryptamine pharmacology effects | 1 result, 1 selected |
selection rationaleselection rationaleDirect study of 4-OH-MiPT (active metabolite of 4-AcO-MiPT) in rodent behavioral models | |||
| 8web search | Web | 4-AcO-MiPT legal status scheduling US UK EU Canada Australia | 10 results, 1 selected |
selection rationaleselection rationaleLegal status not available via PubMed/OpenAlex | |||
| 9web search | Web | 4-AcO-MiPT Shulgin TiHKAL synthesis history first report research chemical | 10 results, 1 selected |
selection rationaleselection rationaleHistorical synthesis/discovery context | |||
| 10document retrieval | PMC (Kozell 2023 full text) | 4-AcO-MiPT specific binding affinity Ki EC50 | 1 result, 1 selected |
selection rationaleselection rationaleCritical quantitative pharmacological data directly for 4-AcO-MiPT | |||
| 11legal status search | Erowid legal status page | 4-AcO-MiPT legal status | 1 result, 1 selected |
selection rationaleselection rationalePrimary legal status source | |||
| 12legal status search | Web search | 4-AcO-MiPT Germany NpSG Sweden Australia Schedule 9 | 10 results, 2 selected |
selection rationaleselection rationaleAdditional legal status by major jurisdiction | |||
| 13literature search | PubMed | 4-OH-MiPT behavioral effects rodents | 1 result, 1 selected |
selection rationaleselection rationaleActive metabolite directly studied | |||
| 14literature search | PubMed | psilocybin pharmacokinetics systematic review | 1 result, 1 selected |
selection rationaleselection rationaleReference pharmacokinetics for 4-OH-MiPT as psilocin analog | |||
| 15document retrieval | UK Legislation (PSA 2016) | — | 1 result, 1 selected |
selection rationaleselection rationaleUK legal framework for 4-AcO-MiPT | |||
| 16literature search | PubMed/OpenAlex | psilocybin analogues SAR structure activity relationships | 1 result, 1 selected |
selection rationaleselection rationaleSystematic SAR study directly covering 4-acetoxy and 4-hydroxy tryptamines | |||
| 17literature search | PubMed | Chadeayne miprocin fumarate crystal structure 4-HO-MiPT | 2 results, 2 selected |
selection rationaleselection rationalePhysical chemistry characterization of the active metabolite | |||
| 18database lookup | PubChem REST API | CID 46783587 CanonicalSMILES synonyms properties | 1 result, 3 selected |
selection rationaleselection rationaleComplete chemical identity data | |||
| 19document retrieval | Google Patents | US11780808B2 crystalline bis-miprocin fumarate synthesis history | 1 result, 2 selected |
selection rationaleselection rationaleHistorical context for 4-HO-MiPT and its acetate ester 4-AcO-MiPT | |||
| 20cross reference | PubMed / Crossref | verify DOIs for Klein 2021 and Chadeayne 2019 | 2 results, 1 selected |
selection rationaleselection rationaleDOI verification per protocol | |||
| 21data extraction | PMC / Kozell 2023 full text | Ki EC50 binding affinity 4-AcO-MiPT 4-OH-MiPT 5-HT2A 5-HT2C 5-HT1A SERT | 1 result, 2 selected |
selection rationaleselection rationalePrimary quantitative pharmacology data for 4-AcO-MiPT and its active metabolite — critical for pharmacology section | |||
| 22literature search | PubMed | tramadol serotonin syndrome opioid mechanism review | 5 results, 2 selected |
selection rationaleselection rationaleMechanistic basis for tramadol-tryptamine serotonin syndrome interaction flagged in brief | |||
| 23literature search | PubMed | serotonin syndrome hallucinogen psychedelic risk serotonergic drug interaction | 2 results, 1 selected |
selection rationaleselection rationaleDirect coverage of serotonin toxicity risk for psychedelics + serotonergic drug combinations | |||
| 24cross reference | Crossref via verify_doi | DOI verification Kozell 2023, Klein 2021, Gatch 2021, Hill 2025 | 4 results, 4 selected |
selection rationaleselection rationaleDOI verification for api_verified status | |||
| 25legal status search | Erowid 4-AcO-MiPT legal status page | 4-AcO-MiPT legal status US Finland Sweden | 1 result, 3 selected |
selection rationaleselection rationalePrimary legal status data for 3 jurisdictions | |||
| 26web search | Web | 4-AcO-MiPT legal status scheduled analog act UK Germany Sweden Australia 2024 2025 | 10 results, 4 selected |
selection rationaleselection rationaleMulti-jurisdiction legal status compilation | |||
| 27document retrieval | PsychonautWiki | 4-AcO-MiPT dose duration pharmacology effects harm reduction | 1 result, 2 selected |
selection rationaleselection rationaleSecondary confirmation of dose/duration data in seed brief | |||
| 28web search | Web | 4-HO-MiPT miprocin Shulgin TiHKAL synthesis history first appearance research chemical | 10 results, 3 selected |
selection rationaleselection rationaleDiscovery and history narrative | |||
| 29literature search | PubMed | Hill Gatch Forster 2025 tryptamine derivatives rodents behavioral discrimination | 1 result, 1 selected |
selection rationaleselection rationaleConfirms 4-OH-MiPT (active metabolite of 4-AcO-MiPT) was studied specifically by DEA-motivated research | |||
Research document (raw, unedited pipeline output)
# Research Output: 4-AcO-MiPT
---
## Chemical Identity
**PubChem CID:** 46783587 [Ref 16]
**IUPAC name:** [3-[2-[methyl(propan-2-yl)amino]ethyl]-1H-indol-4-yl] acetate [Ref 16]
**Molecular formula:** C₁₆H₂₂N₂O₂ [Ref 16]
**Molecular weight:** 274.36 g/mol [Ref 16]
**InChIKey:** CIDMXLOVFPIHDS-UHFFFAOYSA-N [Ref 16]
**SMILES:** Not returned by PubChem CID lookup API in this session; derivable from IUPAC. ⚠️ FLAG: The brief's SMILES field is empty — the generation agent should derive from IUPAC or fetch directly from PubChem record.
**CAS number:** Not returned by PubChem API in this session. ⚠️ FLAG: Should be confirmed from PubChem synonyms list.
**Synonyms/street names:** Mipracetin, O-Acetylmiprocin [Ref 18]
**Discrepancies with seed data:**
- The seed data left Molecular formula, Molecular weight, InChIKey, SMILES, and PubChem CID blank. All have been filled except SMILES (derivable) and CAS (not returned).
- IUPAC name in seed data matches PubChem exactly. ✓
- The systematic name given in the brief ("[3-[2-[methyl(propan-2-yl)amino]ethyl]-1H-indol-4-yl] acetate") is confirmed as correct. ✓
**Stereochemistry:** No chiral centers. 4-AcO-MiPT is achiral — no enantiomers or diastereomers exist.
**Physical properties (4-AcO-MiPT itself):** No published data on melting point, aqueous solubility, or stability was located. ⚠️ FLAG: Absent from published literature.
**Physical properties (active metabolite 4-HO-MiPT):**
Chadeayne et al. (2019 [Ref 10]) characterized the fumarate salt of 4-HO-MiPT as a monohydrate with N–H···O and O–H···O hydrogen bonds forming infinite 2D networks. A second crystalline form of the bis-fumarate salt was reported in 2020 [Ref 11]. These crystal forms apply to the metabolite used as a research reference standard, not to 4-AcO-MiPT itself.
---
## Pharmacology
### Receptor Binding and Functional Potency
Kozell et al. (2023 [Ref 1]) is the primary published source of quantitative receptor pharmacology data for 4-AcO-MiPT. This study tested 21 substituted tryptamines in radioligand binding assays and signal transduction assays (IP-1 accumulation for Gq-coupled receptors; GTPγS binding for 5-HT1A; [³H]5-HT uptake inhibition for SERT).
**4-AcO-MiPT at primary targets:**
| Target | Ki (binding) | EC₅₀ (functional) | Efficacy |
|--------|-------------|-------------------|---------|
| 5-HT2A | 800 ± 100 nM | 445 ± 69 nM (IP-1) | 69.2 ± 1.4% |
| 5-HT2C | 2,230 ± 220 nM | 539 ± 81 nM (IP-1) | 87.2 ± 6.1% |
| 5-HT1A | 11,000 ± 1,200 nM | 8,200 ± 2,100 nM (GTPγS) | 58.3 ± 1.7% |
| SERT | 10,400 ± 1,200 nM (Ki) | 5,800 ± 1,200 nM (IC₅₀ uptake) | N/A |
**Active metabolite 4-OH-MiPT (miprocin) at primary targets** (Kozell et al. 2023 [Ref 1]):
| Target | Ki (binding) | EC₅₀ (functional) | Efficacy |
|--------|-------------|-------------------|---------|
| 5-HT2A | 113 ± 31 nM | 306 ± 11 nM (IP-1) | 74.2 ± 1.8% |
| 5-HT2C | 750 ± 110 nM | 261 ± 45 nM (IP-1) | 98.4 ± 4.4% |
| 5-HT1A | 5,870 ± 430 nM | 2,590 ± 640 nM (GTPγS) | 82.7 ± 2.0% |
| SERT | 483 ± 20 nM (Ki) | 373 ± 16 nM (IC₅₀ uptake) | N/A |
**Key interpretation:** 4-AcO-MiPT has approximately 7× lower 5-HT2A binding affinity (Ki 800 vs. 113 nM) and modestly lower functional potency (EC₅₀ 445 vs. 306 nM) compared to its metabolite 4-OH-MiPT. This ~7-fold potency difference between acetate ester and free hydroxyl forms is consistent with the prodrug hypothesis — the acetate must be hydrolyzed in vivo to generate the pharmacologically active form [Ref 1]. Gatch et al. (2021 [Ref 2]) independently confirmed that 4-hydroxy tryptamines are more potent than corresponding 4-acetoxy forms in rat drug discrimination (DOM-generalization paradigm), further supporting this mechanism.
At 5-HT2A, 4-AcO-MiPT acts as a **partial agonist** (69.2% efficacy vs. a full reference agonist), while 4-OH-MiPT is also partial (74.2%). Both compounds show higher efficacy at 5-HT2C (87–98%). At 5-HT1A, both are partial agonists with weaker binding affinity, which is consistent with other 4-substituted tryptamines [Ref 1]. Neither compound has meaningful SERT affinity at pharmacologically relevant concentrations (SERT IC₅₀ for 4-AcO-MiPT is ~13× its 5-HT2A EC₅₀).
### Signaling Mechanism
Wallach et al. (2023 [Ref 5]) demonstrated that 5-HT2A Gq-pathway (IP-1 accumulation) efficacy — not beta-arrestin2 recruitment — predicts hallucinogenic/psychedelic potential as measured by head-twitch response in mice. 4-AcO-MiPT's partial Gq agonism at 5-HT2A (69.2% efficacy) is consistent with classical psychedelic activity. The same study showed that beta-arrestin-biased ligands induce receptor downregulation and tachyphylaxis, providing a mechanistic framework for the rapid tolerance observed with 4-AcO-MiPT [Ref 5].
Inserra et al. (2021 [Ref 6]) contextualize broader downstream tryptamine effects: 5-HT2A/5-HT1A co-activation, NMDA/AMPA modulation, mTOR-BDNF neuroplasticity cascades, and immunomodulation.
### Structure–Activity Relationships
Klein et al. (2021 [Ref 9]) systematically evaluated 17 tryptamines with 4-hydroxy or 4-acetoxy substitutions and varied N,N-dialkyl groups in mouse head-twitch response and 5-HT2A/2B/2C functional assays. Key findings applicable to 4-AcO-MiPT:
- All 4-hydroxy and 4-acetoxy tryptamines tested were full or partial agonists at 5-HT2A, 5-HT2B, and 5-HT2C.
- 4-AcO-DiPT (the N,N-diisopropyl analog of 4-AcO-MiPT) produced notably longer-lasting effects than other analogs, suggesting the isopropyl substituent may extend activity duration.
- The N-methyl-N-isopropyl substitution pattern in 4-AcO-MiPT (asymmetric) lies between the N,N-dimethyl (shorter duration) and N,N-diisopropyl (longer duration) compounds in the SAR space [Ref 9]. ⚠️ FLAG: 4-AcO-MiPT was not itself directly tested in Klein 2021 — this inference is by structural analogy.
Hill et al. (2025 [Ref 7]) reported behavioral effects of 4-OH-MiPT in rodent models (drug discrimination, locomotor activity) alongside 5-MeO-DBT and 5-Cl-DMT, identifying 4-OH-MiPT as a DEA-designated tryptamine derivative of concern. Specific ED₅₀ and discrimination data from this paper are not fully available in the abstract — full paper details not retrieved. ⚠️ FLAG: Full-text ED₅₀/behavioral data for 4-OH-MiPT from Hill 2025 not available in abstract.
### Pharmacokinetics
**No published human pharmacokinetic data exist specifically for 4-AcO-MiPT.** All pharmacokinetic inferences below are by structural analogy and should be clearly labeled as such.
**Prodrug hydrolysis (inferred from analog data):** Malaca et al. (2022 [Ref 3]) studied 4-AcO-DiPT (the N,N-diisopropyl analog) in human hepatocytes. Primary metabolite is 4-OH-DiPT via ester hydrolysis. Phase II metabolites include glucuronides and sulfate conjugates. N-oxidation and N-dealkylation also occur. Six metabolites were identified total. By structural analogy, 4-AcO-MiPT is expected to undergo analogous ester hydrolysis to yield 4-OH-MiPT as its primary active metabolite [Ref 3]. This is also consistent with the well-characterized psilocybin → psilocin conversion [Ref 8].
**Active metabolite PK (inferred from psilocin class data):** Meshkat et al. (2025 [Ref 8]) systematic review of psilocybin pharmacokinetics in 112 humans: psilocin (4-OH-DMT, the structural DMT-analog homolog to 4-OH-MiPT) shows Tmax 1.8–4 h, bioavailability 52.7 ± 20%, Vd 277–1016 L, elimination half-life 1.5–4 h. Primary CYP enzymes: CYP2D6 and CYP3A4; secondary: MAO-A. These figures are informative for 4-OH-MiPT but should not be cited as direct data for 4-AcO-MiPT [Ref 8]. ⚠️ FLAG: All PK data for 4-AcO-MiPT is by structural analogy — no direct human PK studies exist.
---
## History
**Discovery and synthesis of the parent compound (4-HO-MiPT / miprocin):**
4-HO-MiPT was first synthesized and published by David Repke and colleagues in 1981. Alexander Shulgin reportedly evaluated the compound's effects in himself as early as 1979, prior to the Repke publication. Shulgin described 4-HO-MiPT as the most interesting compound in a series of MiPT oxygen-substituted analogs, noting classical hallucinogen effects. A description of 4-HO-MiPT (miprocin) is included in Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved) [Ref 19], where he records a self-trial of 12 mg as "richly insightful and highly erotic."
**4-AcO-MiPT as a Shulgin homologue:**
Shulgin and Shulgin also experimented with 4-AcO-MiPT alongside 4-AcO-DMT and 4-AcO-DET, finding it to be a potent psychedelic drug. The acetate ester is described as the pro-drug acetylated form of miprocin [Ref 18]. The compound appears in the research chemical literature as a structural analog of psilocybin (4-AcO-DMT is the direct N,N-dimethyl homolog).
**Research chemical market emergence:**
4-AcO-MiPT emerged on online research chemical markets during the late 2000s to early 2010s, typically distributed in fumarate salt form. Its legal grey status in many jurisdictions during this period enabled open sale [Ref 18].
**Pharmacological research timeline:**
- 2019: Chadeayne et al. published crystal structure of 4-HO-MiPT fumarate [Ref 10].
- 2020: Chadeayne et al. published a second crystalline form [Ref 11].
- 2021: Klein et al. SAR study of psilocybin analogs including 4-AcO/4-HO class [Ref 9]; Gatch et al. discriminative stimulus study covering the class [Ref 2].
- 2023: Kozell et al. first published binding affinity and functional potency data directly for 4-AcO-MiPT and 4-OH-MiPT [Ref 1]; Wallach et al. identified Gq-pathway as key for psychedelic potential [Ref 5].
- 2025: Hill et al. reported behavioral studies of 4-OH-MiPT following DEA designation as a substance of concern [Ref 7].
**No institutional or clinical history** of therapeutic development for 4-AcO-MiPT has been identified. No IND applications, patents, or clinical trial sponsorships for 4-AcO-MiPT itself were found.
---
## Subjective Effects
**No controlled human studies on the subjective effects of 4-AcO-MiPT exist in the published literature.** All descriptions of subjective effects come from user self-reports, online communities, and Shulgin's self-experiments (TiHKAL [Ref 19]). These should be clearly labeled as user-report-only data in the article.
**Shulgin's account (from TiHKAL [Ref 19]):** Primarily reported for 4-HO-MiPT (the active metabolite). Described at 12 mg as richly insightful, highly erotic, with classical hallucinogen effects. Qualitative character similar to other 4-substituted tryptamines.
**Community-reported effects (from PsychonautWiki [Ref 18], user-report only):**
The effects taxonomy in the seed data reflects community reports and is reproduced below with this provenance label:
*Body:* Nasal congestion, watery eyes, spontaneous body sensations (tingling/rushing), yawning, sedation (lower doses), wakefulness (higher doses), pupil dilation.
*Perception:* Synesthesia, auditory distortion, after-images, tracers, object transformations, color alteration, symmetrical texture repetition, visual diffraction, perspective distortion, color enhancement, internal hallucinations, depth perception distortion, music enhancement, visual acuity enhancement, brightness alteration, visual drifting, auditory hallucinations.
*Transpersonal:* Existential realization, entity contact, unity and interconnectedness.
*Cognition:* Delusions, novelty enhancement, thought connectivity, pattern recognition enhancement, thought loops, conceptual thinking, immersion enhancement, memory suppression.
*Emotion:* Emotional enhancement.
*Time perception:* Time alteration, déjà vu.
*Insight:* Personal insight.
**Community-reported dose/duration data (user-report only; confirmed consistent with PsychonautWiki [Ref 18, 20]):**
- Threshold: 5 mg (oral)
- Light: 10–15 mg (oral)
- Common: 15–20 mg (oral)
- Strong: 20–35 mg (oral)
- Heavy: 35+ mg (oral)
- Onset: 20–60 min | Come-up: 1–2 h | Peak: 1.5–3 h | Offset: 1–2 h | After-effects: 2–4 h | Total: 4–8 h
These values match the seed data exactly. No correction is warranted from published sources (no published dose studies exist). ⚠️ FLAG: All dose and duration data is user-report only — no controlled dose-finding or pharmacokinetic study in humans exists. Dose-sensitivity value absent from all sources.
---
## Safety & Toxicity
**LD₅₀:** No published LD₅₀ data for 4-AcO-MiPT in any species. Seed data states "toxic dose is unknown." This is accurate. ⚠️ FLAG: Safety-critical — no dose-lethality data exists.
**Human toxicity:** No published case reports of adverse events, overdose, or death specifically attributable to 4-AcO-MiPT were identified in any database searched (PubMed, OpenAlex, Erowid, web searches).
**Class-level toxicity context:**
Tittarelli et al. (2015 [Ref 4]) reviewed tryptamine NPS toxicity broadly, noting that acute toxicity can include sympathomimetic effects (tachycardia, hypertension, hyperthermia), seizures, and serotonin syndrome when combined with serotonergic agents, particularly MAOIs. Individual reports of tryptamine overdoses exist in the broader NPS surveillance literature but none specific to 4-AcO-MiPT.
Helander et al. (2014 [Ref 15]) documented clinical presentations of tryptamine NPS intoxications in Swedish emergency rooms via the STRIDA project, noting that polydrug use complicates attribution. No 4-AcO-MiPT-specific cases identified.
**Psychological risks:** No published controlled data. By class inference, risk of anxiety, panic, and psychedelic crisis is expected at higher doses, particularly in unsupported settings or with pre-existing vulnerability to psychosis. Not documented specifically for 4-AcO-MiPT. ⚠️ FLAG: All psychological risk data is class-level inference.
**Cardiovascular risks:** No specific published data. Class-level expectation of mild sympathomimetic effects (pupil dilation confirmed in user reports). ⚠️ FLAG: Absence of data, not confirmed absence of risk.
**Organ toxicity:** No published data. No hepatotoxicity or nephrotoxicity data specific to 4-AcO-MiPT. ⚠️ FLAG.
---
## Harm Reduction
**No published harm reduction protocols specific to 4-AcO-MiPT exist.** All recommendations below are by class-level inference from published psychedelic harm reduction literature.
**Set and setting:** Standard psychedelic harm reduction applies — minimize environmental stressors, ensure trusted support person. Not specific to this compound.
**Reagent testing:** 4-AcO-MiPT is expected to react with Ehrlich reagent (DMT-sensitive indole test) due to the indole core. No published validation of specific color response for 4-AcO-MiPT was found. ⚠️ FLAG: Testing guidance is inferred, not validated.
**Contraindications:** No published contraindication list specific to 4-AcO-MiPT. Class-level contraindications include:
- Concurrent MAOI use (severe serotonin syndrome risk)
- Concurrent tramadol use (see Interactions section)
- Concurrent SSRI/SNRI use (serotonin syndrome risk; also attenuates effects)
- History of personal or family psychosis or schizophrenia spectrum disorders
- Cardiovascular disease (sympathomimetic effects)
**Emergency guidance:** Standard psychedelic crisis protocols apply. No specific antidote exists. Serotonin syndrome management follows standard guidelines (cyproheptadine, benzodiazepines, supportive care). ⚠️ FLAG: Not substance-specific.
---
## Tolerance & Dependence
**Tolerance:** Rapid tolerance development is expected following the class-wide 5-HT2A receptor downregulation mechanism (Wallach et al. 2023 [Ref 5]). The seed data states "buildup: almost immediately after ingestion; half-life: 3 days; full reset: 7 days; cross-tolerances: psychedelic." These values match community consensus for the tryptamine psychedelic class. ⚠️ FLAG: No published pharmacokinetic or receptor occupancy data confirm these specific values for 4-AcO-MiPT. Values are class-level inference consistent with the 5-HT2A downregulation mechanism [Ref 5].
**Cross-tolerance:** Cross-tolerance to other serotonergic psychedelics (LSD, psilocybin, DMT class) expected via shared 5-HT2A downregulation mechanism [Ref 5]. This is class-level inference — no direct cross-tolerance studies with 4-AcO-MiPT exist.
**Dependence liability:** No published dependence liability assessment specific to 4-AcO-MiPT. The seed data states "not habit-forming," consistent with the general profile of psychedelic tryptamines. Gatch et al. (2021 [Ref 2]) noted that substituted tryptamines suggest abuse liability "similar to DOM" based on drug discrimination data, but this refers to generalization of drug stimulus, not compulsive use patterns. No evidence of physical dependence, withdrawal syndrome, or escalating use is documented for 4-AcO-MiPT or close analogs. ⚠️ FLAG: Dependence characterization is by class inference.
---
## Interactions
**Tramadol — DANGEROUS (seed data flag)**
The seed data flags the tramadol interaction as dangerous. This is consistent with published mechanisms:
- Tramadol inhibits the serotonin transporter (SERT), functionally acting as an SSRI and increasing synaptic serotonin concentrations (Baldo 2018 [Ref 13]; Roulet et al. 2021).
- Combined with 5-HT2A agonism from 4-AcO-MiPT/4-OH-MiPT, the serotonin system is doubly challenged, creating risk of serotonin syndrome.
- Gudla et al. (2026 [Ref 14]) systematic review documents tramadol-induced serotonin syndrome as a real and documented adverse outcome.
- Malcolm & Thomas (2022 [Ref 12]) note that psychedelic 5-HT2A agonists combined with serotonergic drugs present clinically important drug-drug interaction risks.
- **Assessment: The dangerous classification is mechanistically well-supported. No specific case reports of tramadol + 4-AcO-MiPT serotonin syndrome were found, but the mechanistic basis is strong.**
**Cannabis — Unknown**
Seed data flags as unknown interaction. No published data found. Cannot characterize further. ⚠️ FLAG: Insufficient evidence.
**MAOIs — Not listed in seed data; class-level severe risk**
MAO-A inhibitors block breakdown of serotonin. Combined with a 5-HT2A agonist, potentiation and serotonin toxicity risk is expected. ⚠️ FLAG: Interaction not listed in seed data but is an important contraindication for the class (Tittarelli 2015 [Ref 4]). Recommend flagging for editorial review.
**SSRIs/SNRIs:**
Expected to attenuate psychedelic effects via 5-HT2A downregulation (chronic SSRI use) and potentially increase serotonin syndrome risk acutely. No specific published data for 4-AcO-MiPT.
**CYP enzyme interactions:**
By structural analogy to psilocin, CYP2D6 and CYP3A4 inhibitors may increase 4-OH-MiPT plasma levels. No published data. ⚠️ FLAG.
---
## Legal Status
*(Sources: Erowid [Ref 17], web search compilation [Ref 18]; all legal status data is web-retrieved, not api_verified)*
| Jurisdiction | Status | Basis | Date |
|---|---|---|---|
| United States | Unscheduled | No direct scheduling; Federal Analog Act potentially applicable as psilocin analog | — |
| United Kingdom | Class A | Tryptamine catch-all clause (Misuse of Drugs Act 1971); 4-HO-MiPT is Class A; as its ester, 4-AcO-MiPT is also Class A | — |
| Germany | Controlled (NpSG) | New Psychoactive Substances Act | July 18, 2019 |
| Sweden | Scheduled | Lagen om förbud mot vissa hälsofarliga varor (health-hazardous substances) | November 1, 2005 |
| Finland | Banned | Finnish regulation prohibiting 100+ psychoactive chemicals | December 2014 |
| Canada | Not controlled | Not listed in Schedule | — |
| Australia | No specific data found | May fall under analog provisions; not confirmed | — |
⚠️ FLAG: Legal status data is web-retrieved (Erowid, PsychonautWiki, web search). All jurisdictions should be independently verified before publication.
---
## Clinical Trials
**No clinical trials found.** A search of ClinicalTrials.gov for "4-AcO-MiPT tryptamine psychedelic" returned zero results. No active, recruiting, completed, or terminated trials involving 4-AcO-MiPT identified.
---
## Community Feedback Analysis
**No community feedback was submitted in Part A2 of the brief.**
No community feedback submitted. Seed data was evaluated against published sources; all discrepancies are noted in the Gaps & Flags section below.
---
## Gaps & Flags
The following are data gaps and flags for editorial review. Items marked ⚠️ SAFETY are safety-critical.
### Chemical Identity
1. **SMILES string absent from seed data.** Not returned by PubChem API in this session — derivable from IUPAC but should be explicitly populated from PubChem compound page.
2. **CAS number not confirmed.** PubChem lookup did not return CAS in this session — should be confirmed from PubChem synonym list.
### Pharmacology
3. **No direct human pharmacokinetic data exists for 4-AcO-MiPT.** Bioavailability, Tmax, Cmax, volume of distribution, elimination half-life, and CYP enzyme involvement are all inferred from structural analogs (4-AcO-DiPT, psilocin). These must be clearly labeled as inferences in the article.
4. **4-AcO-MiPT was not directly tested in the Klein 2021 SAR study** (Ref 9) or the Gatch 2021 drug discrimination study (Ref 2). The most directly relevant study is Kozell 2023 (Ref 1), which provides binding affinity data. All behavioral and SAR statements beyond Ref 1 are by structural analogy.
5. **Full-text behavioral data for 4-OH-MiPT from Hill 2025 (Ref 7) not available** in abstract — specific ED₅₀, discrimination substitution rates, and locomotor data could not be extracted.
### Safety ⚠️ SAFETY
6. **No published LD₅₀ data** for 4-AcO-MiPT in any species. Toxic dose is genuinely unknown.
7. **No published adverse event case reports or overdose reports** specific to 4-AcO-MiPT. Safety profile is inferred from class data.
8. **MAOI interaction not listed in seed data interactions** but represents a high-severity class-level risk. Recommend adding as "dangerous" interaction.
9. **Dose/duration data is entirely from community reports (user-report only).** No controlled dose-finding, challenge, or pharmacokinetic study in humans exists. Dose sensitivity value is absent from all sources.
### Tolerance & Dependence
10. **Tolerance build-up rate (half-life 3 days, full reset 7 days) is community consensus** — mechanistically plausible via 5-HT2A downregulation (Ref 5) but not directly measured for 4-AcO-MiPT.
### Interactions
11. **Cannabis interaction classified as "unknown"** — no published data found to characterize this in either direction.
12. **Tramadol interaction ("dangerous") is mechanistically well-supported** (SERT inhibition + 5-HT2A agonism → serotonin syndrome risk) but no case report specific to this combination was found. Confidence: high (mechanism), moderate (case evidence).
### Legal Status
13. **All legal status data is web-retrieved** (Erowid, PsychonautWiki) and should be independently verified before publication. Australia scheduling status not confirmed.
### Clinical
14. **No clinical trials exist** for 4-AcO-MiPT. No institutional research program identified.
### Physical Properties
15. **No melting point, solubility, or stability data published for 4-AcO-MiPT.** Only physical characterization data pertains to the active metabolite (4-HO-MiPT fumarate salts, Refs 10–11).
---
*Research completed: 2026-05-03. Searches conducted via PubMed, OpenAlex, PubChem, ClinicalTrials.gov, Crossref, Erowid, PsychonautWiki, and web search. 29 research steps recorded. 20 unique citations in registry.*